WO1991005876A1 - Human cytomegalovirus-specific monoclonal antibody cocktail - Google Patents
Human cytomegalovirus-specific monoclonal antibody cocktail Download PDFInfo
- Publication number
- WO1991005876A1 WO1991005876A1 PCT/US1990/006017 US9006017W WO9105876A1 WO 1991005876 A1 WO1991005876 A1 WO 1991005876A1 US 9006017 W US9006017 W US 9006017W WO 9105876 A1 WO9105876 A1 WO 9105876A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- hcmv
- human cytomegalovirus
- immunoglobulins
- immunoglobulin
- gci
- Prior art date
Links
- 241000701024 Human betaherpesvirus 5 Species 0.000 title claims abstract description 227
- 239000000203 mixture Substances 0.000 claims abstract description 106
- 238000000034 method Methods 0.000 claims abstract description 35
- 238000011282 treatment Methods 0.000 claims abstract description 22
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 17
- 229940043517 specific immunoglobulins Drugs 0.000 claims abstract description 14
- 208000024697 human cytomegalovirus infection Diseases 0.000 claims abstract 9
- 108060003951 Immunoglobulin Proteins 0.000 claims description 115
- 102000018358 immunoglobulin Human genes 0.000 claims description 115
- 108090000288 Glycoproteins Proteins 0.000 claims description 108
- 102000003886 Glycoproteins Human genes 0.000 claims description 108
- 230000003472 neutralizing effect Effects 0.000 claims description 56
- 229940072221 immunoglobulins Drugs 0.000 claims description 55
- 101710170453 Glycoprotein 55 Proteins 0.000 claims description 40
- 230000000694 effects Effects 0.000 claims description 39
- 230000000840 anti-viral effect Effects 0.000 claims description 38
- 230000000295 complement effect Effects 0.000 claims description 37
- 241001529936 Murinae Species 0.000 claims description 29
- 230000001419 dependent effect Effects 0.000 claims description 27
- 230000003834 intracellular effect Effects 0.000 claims description 21
- 238000003556 assay Methods 0.000 claims description 20
- 101710121417 Envelope glycoprotein Proteins 0.000 claims description 17
- 210000000056 organ Anatomy 0.000 claims description 16
- 230000009257 reactivity Effects 0.000 claims description 15
- 210000001519 tissue Anatomy 0.000 claims description 15
- 230000027455 binding Effects 0.000 claims description 14
- 230000001225 therapeutic effect Effects 0.000 claims description 14
- 239000012634 fragment Substances 0.000 claims description 11
- 230000002401 inhibitory effect Effects 0.000 claims description 11
- 238000001514 detection method Methods 0.000 claims description 10
- 238000010166 immunofluorescence Methods 0.000 claims description 9
- 102100040510 Galectin-3-binding protein Human genes 0.000 claims description 8
- 101800001271 Surface protein Proteins 0.000 claims description 8
- 210000001185 bone marrow Anatomy 0.000 claims description 8
- 102000004190 Enzymes Human genes 0.000 claims description 7
- 108090000790 Enzymes Proteins 0.000 claims description 7
- 230000001747 exhibiting effect Effects 0.000 claims description 7
- 102000018071 Immunoglobulin Fc Fragments Human genes 0.000 claims description 5
- 108010091135 Immunoglobulin Fc Fragments Proteins 0.000 claims description 5
- 238000006243 chemical reaction Methods 0.000 claims description 5
- 239000007788 liquid Substances 0.000 claims description 4
- 238000011321 prophylaxis Methods 0.000 claims description 4
- 241000282412 Homo Species 0.000 claims description 3
- 239000003937 drug carrier Substances 0.000 claims description 3
- 239000012530 fluid Substances 0.000 claims description 3
- 238000003127 radioimmunoassay Methods 0.000 claims description 3
- 238000003018 immunoassay Methods 0.000 claims description 2
- 102100021696 Syncytin-1 Human genes 0.000 claims 6
- 239000003550 marker Substances 0.000 claims 3
- 241000701022 Cytomegalovirus Species 0.000 claims 1
- 230000002163 immunogen Effects 0.000 abstract description 6
- 238000003745 diagnosis Methods 0.000 abstract description 3
- 206010011831 Cytomegalovirus infection Diseases 0.000 description 48
- 210000004027 cell Anatomy 0.000 description 41
- 108090000623 proteins and genes Proteins 0.000 description 38
- 102000004169 proteins and genes Human genes 0.000 description 32
- 241000700605 Viruses Species 0.000 description 29
- 210000002845 virion Anatomy 0.000 description 24
- 238000002360 preparation method Methods 0.000 description 20
- 208000015181 infectious disease Diseases 0.000 description 18
- 238000000338 in vitro Methods 0.000 description 14
- 230000002195 synergetic effect Effects 0.000 description 12
- 102100034349 Integrase Human genes 0.000 description 11
- 230000008901 benefit Effects 0.000 description 11
- 238000006386 neutralization reaction Methods 0.000 description 11
- 206010010356 Congenital anomaly Diseases 0.000 description 10
- 102000006395 Globulins Human genes 0.000 description 10
- 108010044091 Globulins Proteins 0.000 description 10
- 238000001179 sorption measurement Methods 0.000 description 10
- 230000003612 virological effect Effects 0.000 description 10
- 230000004044 response Effects 0.000 description 9
- 239000000427 antigen Substances 0.000 description 8
- 108091007433 antigens Proteins 0.000 description 8
- 102000036639 antigens Human genes 0.000 description 8
- 230000003190 augmentative effect Effects 0.000 description 8
- 230000009089 cytolysis Effects 0.000 description 8
- 210000004408 hybridoma Anatomy 0.000 description 8
- 238000004519 manufacturing process Methods 0.000 description 8
- 230000035515 penetration Effects 0.000 description 8
- YBYRMVIVWMBXKQ-UHFFFAOYSA-N phenylmethanesulfonyl fluoride Chemical compound FS(=O)(=O)CC1=CC=CC=C1 YBYRMVIVWMBXKQ-UHFFFAOYSA-N 0.000 description 8
- 239000002953 phosphate buffered saline Substances 0.000 description 8
- 239000000243 solution Substances 0.000 description 8
- 238000001262 western blot Methods 0.000 description 8
- 208000030507 AIDS Diseases 0.000 description 7
- 241000700584 Simplexvirus Species 0.000 description 7
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 7
- 230000000521 hyperimmunizing effect Effects 0.000 description 7
- 230000005764 inhibitory process Effects 0.000 description 7
- 230000002829 reductive effect Effects 0.000 description 7
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 6
- 241000701085 Human alphaherpesvirus 3 Species 0.000 description 6
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 6
- 229940088598 enzyme Drugs 0.000 description 6
- 239000000284 extract Substances 0.000 description 6
- 239000000499 gel Substances 0.000 description 6
- 230000002458 infectious effect Effects 0.000 description 6
- 230000010464 virion assembly Effects 0.000 description 6
- 206010003445 Ascites Diseases 0.000 description 5
- 241000725303 Human immunodeficiency virus Species 0.000 description 5
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 5
- 210000003719 b-lymphocyte Anatomy 0.000 description 5
- 239000010836 blood and blood product Substances 0.000 description 5
- 229940125691 blood product Drugs 0.000 description 5
- 230000001413 cellular effect Effects 0.000 description 5
- 238000009472 formulation Methods 0.000 description 5
- 230000003053 immunization Effects 0.000 description 5
- 230000009467 reduction Effects 0.000 description 5
- 230000010076 replication Effects 0.000 description 5
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 5
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 4
- 238000011725 BALB/c mouse Methods 0.000 description 4
- 241000283707 Capra Species 0.000 description 4
- 241000699666 Mus <mouse, genus> Species 0.000 description 4
- 239000007983 Tris buffer Substances 0.000 description 4
- 230000005875 antibody response Effects 0.000 description 4
- 239000000872 buffer Substances 0.000 description 4
- 238000012512 characterization method Methods 0.000 description 4
- 238000011161 development Methods 0.000 description 4
- 238000010790 dilution Methods 0.000 description 4
- 239000012895 dilution Substances 0.000 description 4
- 210000002950 fibroblast Anatomy 0.000 description 4
- 238000004128 high performance liquid chromatography Methods 0.000 description 4
- 239000000463 material Substances 0.000 description 4
- 230000002085 persistent effect Effects 0.000 description 4
- 238000002962 plaque-reduction assay Methods 0.000 description 4
- 230000035945 sensitivity Effects 0.000 description 4
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 4
- 229920000936 Agarose Polymers 0.000 description 3
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 3
- 108010010803 Gelatin Proteins 0.000 description 3
- 241000701044 Human gammaherpesvirus 4 Species 0.000 description 3
- 239000002671 adjuvant Substances 0.000 description 3
- 239000003443 antiviral agent Substances 0.000 description 3
- 238000011888 autopsy Methods 0.000 description 3
- 230000000903 blocking effect Effects 0.000 description 3
- 210000000170 cell membrane Anatomy 0.000 description 3
- 201000004709 chorioretinitis Diseases 0.000 description 3
- UQLDLKMNUJERMK-UHFFFAOYSA-L di(octadecanoyloxy)lead Chemical compound [Pb+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O UQLDLKMNUJERMK-UHFFFAOYSA-L 0.000 description 3
- 239000012091 fetal bovine serum Substances 0.000 description 3
- 230000006870 function Effects 0.000 description 3
- 239000008273 gelatin Substances 0.000 description 3
- 229920000159 gelatin Polymers 0.000 description 3
- 235000019322 gelatine Nutrition 0.000 description 3
- 235000011852 gelatine desserts Nutrition 0.000 description 3
- 238000002649 immunization Methods 0.000 description 3
- 239000012133 immunoprecipitate Substances 0.000 description 3
- 230000006872 improvement Effects 0.000 description 3
- 238000007918 intramuscular administration Methods 0.000 description 3
- 238000001990 intravenous administration Methods 0.000 description 3
- 239000012528 membrane Substances 0.000 description 3
- 235000020030 perry Nutrition 0.000 description 3
- 229920002401 polyacrylamide Polymers 0.000 description 3
- 239000000843 powder Substances 0.000 description 3
- 230000000069 prophylactic effect Effects 0.000 description 3
- 230000007420 reactivation Effects 0.000 description 3
- 230000003362 replicative effect Effects 0.000 description 3
- 210000002966 serum Anatomy 0.000 description 3
- 210000001626 skin fibroblast Anatomy 0.000 description 3
- 241000701161 unidentified adenovirus Species 0.000 description 3
- 241001529453 unidentified herpesvirus Species 0.000 description 3
- TVZGACDUOSZQKY-LBPRGKRZSA-N 4-aminofolic acid Chemical compound C1=NC2=NC(N)=NC(N)=C2N=C1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 TVZGACDUOSZQKY-LBPRGKRZSA-N 0.000 description 2
- 108010088751 Albumins Proteins 0.000 description 2
- 102000009027 Albumins Human genes 0.000 description 2
- 206010057248 Cell death Diseases 0.000 description 2
- 238000012286 ELISA Assay Methods 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 2
- CEAZRRDELHUEMR-URQXQFDESA-N Gentamicin Chemical compound O1[C@H](C(C)NC)CC[C@@H](N)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](NC)[C@@](C)(O)CO2)O)[C@H](N)C[C@@H]1N CEAZRRDELHUEMR-URQXQFDESA-N 0.000 description 2
- 108700005091 Immunoglobulin Genes Proteins 0.000 description 2
- 208000029523 Interstitial Lung disease Diseases 0.000 description 2
- 241000699670 Mus sp. Species 0.000 description 2
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 2
- 206010035226 Plasma cell myeloma Diseases 0.000 description 2
- IQFYYKKMVGJFEH-XLPZGREQSA-N Thymidine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 IQFYYKKMVGJFEH-XLPZGREQSA-N 0.000 description 2
- 208000036142 Viral infection Diseases 0.000 description 2
- 108070000030 Viral receptors Proteins 0.000 description 2
- 229960003896 aminopterin Drugs 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 230000000890 antigenic effect Effects 0.000 description 2
- 239000011324 bead Substances 0.000 description 2
- 230000008827 biological function Effects 0.000 description 2
- 238000004113 cell culture Methods 0.000 description 2
- 238000005119 centrifugation Methods 0.000 description 2
- 238000010367 cloning Methods 0.000 description 2
- 239000000470 constituent Substances 0.000 description 2
- 230000009260 cross reactivity Effects 0.000 description 2
- 231100000135 cytotoxicity Toxicity 0.000 description 2
- 230000007423 decrease Effects 0.000 description 2
- 239000003085 diluting agent Substances 0.000 description 2
- 210000003754 fetus Anatomy 0.000 description 2
- MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 2
- 230000005714 functional activity Effects 0.000 description 2
- 230000004927 fusion Effects 0.000 description 2
- 229940072360 garamycin Drugs 0.000 description 2
- 239000001963 growth medium Substances 0.000 description 2
- 208000006454 hepatitis Diseases 0.000 description 2
- 231100000283 hepatitis Toxicity 0.000 description 2
- 238000012872 hydroxylapatite chromatography Methods 0.000 description 2
- FDGQSTZJBFJUBT-UHFFFAOYSA-N hypoxanthine Chemical compound O=C1NC=NC2=C1NC=N2 FDGQSTZJBFJUBT-UHFFFAOYSA-N 0.000 description 2
- 230000001900 immune effect Effects 0.000 description 2
- 238000001114 immunoprecipitation Methods 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 238000007912 intraperitoneal administration Methods 0.000 description 2
- 238000001155 isoelectric focusing Methods 0.000 description 2
- 230000002147 killing effect Effects 0.000 description 2
- 230000000670 limiting effect Effects 0.000 description 2
- 210000004698 lymphocyte Anatomy 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 230000001404 mediated effect Effects 0.000 description 2
- 239000002609 medium Substances 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 201000000050 myeloid neoplasm Diseases 0.000 description 2
- 239000000825 pharmaceutical preparation Substances 0.000 description 2
- 239000002243 precursor Substances 0.000 description 2
- 108090000765 processed proteins & peptides Proteins 0.000 description 2
- 230000000750 progressive effect Effects 0.000 description 2
- 230000002035 prolonged effect Effects 0.000 description 2
- 230000006337 proteolytic cleavage Effects 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- 238000011084 recovery Methods 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 238000012216 screening Methods 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 210000004989 spleen cell Anatomy 0.000 description 2
- 238000010186 staining Methods 0.000 description 2
- 108010051423 streptavidin-agarose Proteins 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 239000000758 substrate Substances 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 230000009385 viral infection Effects 0.000 description 2
- 230000001790 virustatic effect Effects 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- YMXHPSHLTSZXKH-RVBZMBCESA-N (2,5-dioxopyrrolidin-1-yl) 5-[(3as,4s,6ar)-2-oxo-1,3,3a,4,6,6a-hexahydrothieno[3,4-d]imidazol-4-yl]pentanoate Chemical compound C([C@H]1[C@H]2NC(=O)N[C@H]2CS1)CCCC(=O)ON1C(=O)CCC1=O YMXHPSHLTSZXKH-RVBZMBCESA-N 0.000 description 1
- ZEXCWMXGMUJPEN-QQCVYQHSSA-N (2r,3r,4r,5s)-hexane-1,2,3,4,5,6-hexol;phenylmethanediol Chemical compound OC(O)C1=CC=CC=C1.OC(O)C1=CC=CC=C1.OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO ZEXCWMXGMUJPEN-QQCVYQHSSA-N 0.000 description 1
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 1
- MSWZFWKMSRAUBD-IVMDWMLBSA-N 2-amino-2-deoxy-D-glucopyranose Chemical compound N[C@H]1C(O)O[C@H](CO)[C@@H](O)[C@@H]1O MSWZFWKMSRAUBD-IVMDWMLBSA-N 0.000 description 1
- QRXMUCSWCMTJGU-UHFFFAOYSA-N 5-bromo-4-chloro-3-indolyl phosphate Chemical compound C1=C(Br)C(Cl)=C2C(OP(O)(=O)O)=CNC2=C1 QRXMUCSWCMTJGU-UHFFFAOYSA-N 0.000 description 1
- 206010000807 Acute HIV infection Diseases 0.000 description 1
- DWRXFEITVBNRMK-UHFFFAOYSA-N Beta-D-1-Arabinofuranosylthymine Natural products O=C1NC(=O)C(C)=CN1C1C(O)C(O)C(CO)O1 DWRXFEITVBNRMK-UHFFFAOYSA-N 0.000 description 1
- 208000004434 Calcinosis Diseases 0.000 description 1
- 241000700199 Cavia porcellus Species 0.000 description 1
- VYZAMTAEIAYCRO-BJUDXGSMSA-N Chromium-51 Chemical compound [51Cr] VYZAMTAEIAYCRO-BJUDXGSMSA-N 0.000 description 1
- 108090000317 Chymotrypsin Proteins 0.000 description 1
- 101710094648 Coat protein Proteins 0.000 description 1
- 108091026890 Coding region Proteins 0.000 description 1
- 206010062343 Congenital infection Diseases 0.000 description 1
- BWGNESOTFCXPMA-UHFFFAOYSA-N Dihydrogen disulfide Chemical compound SS BWGNESOTFCXPMA-UHFFFAOYSA-N 0.000 description 1
- 239000004606 Fillers/Extenders Substances 0.000 description 1
- FZHXIRIBWMQPQF-UHFFFAOYSA-N Glc-NH2 Natural products O=CC(N)C(O)C(O)C(O)CO FZHXIRIBWMQPQF-UHFFFAOYSA-N 0.000 description 1
- 208000031886 HIV Infections Diseases 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- UGQMRVRMYYASKQ-UHFFFAOYSA-N Hypoxanthine nucleoside Natural products OC1C(O)C(CO)OC1N1C(NC=NC2=O)=C2N=C1 UGQMRVRMYYASKQ-UHFFFAOYSA-N 0.000 description 1
- 102000018297 Immunoglobulin subtype Human genes 0.000 description 1
- 108050007411 Immunoglobulin subtype Proteins 0.000 description 1
- 206010062016 Immunosuppression Diseases 0.000 description 1
- 206010021882 Infections and infestations congenital Diseases 0.000 description 1
- 208000007766 Kaposi sarcoma Diseases 0.000 description 1
- 208000012902 Nervous system disease Diseases 0.000 description 1
- 206010029240 Neuritis Diseases 0.000 description 1
- 239000000020 Nitrocellulose Substances 0.000 description 1
- 208000001388 Opportunistic Infections Diseases 0.000 description 1
- 241000609499 Palicourea Species 0.000 description 1
- 206010034133 Pathogen resistance Diseases 0.000 description 1
- 208000037581 Persistent Infection Diseases 0.000 description 1
- 102000004160 Phosphoric Monoester Hydrolases Human genes 0.000 description 1
- 108090000608 Phosphoric Monoester Hydrolases Proteins 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 229920001213 Polysorbate 20 Polymers 0.000 description 1
- 206010037213 Psychomotor retardation Diseases 0.000 description 1
- 108010090804 Streptavidin Proteins 0.000 description 1
- 206010058874 Viraemia Diseases 0.000 description 1
- 230000010530 Virus Neutralization Effects 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 125000003275 alpha amino acid group Chemical group 0.000 description 1
- 238000005349 anion exchange Methods 0.000 description 1
- 238000002832 anti-viral assay Methods 0.000 description 1
- 238000009175 antibody therapy Methods 0.000 description 1
- 230000010056 antibody-dependent cellular cytotoxicity Effects 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 230000003416 augmentation Effects 0.000 description 1
- 239000003855 balanced salt solution Substances 0.000 description 1
- MSWZFWKMSRAUBD-UHFFFAOYSA-N beta-D-galactosamine Natural products NC1C(O)OC(CO)C(O)C1O MSWZFWKMSRAUBD-UHFFFAOYSA-N 0.000 description 1
- IQFYYKKMVGJFEH-UHFFFAOYSA-N beta-L-thymidine Natural products O=C1NC(=O)C(C)=CN1C1OC(CO)C(O)C1 IQFYYKKMVGJFEH-UHFFFAOYSA-N 0.000 description 1
- 230000031018 biological processes and functions Effects 0.000 description 1
- 229960000074 biopharmaceutical Drugs 0.000 description 1
- 238000001574 biopsy Methods 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 230000002308 calcification Effects 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 230000007910 cell fusion Effects 0.000 description 1
- 239000013592 cell lysate Substances 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 201000008208 central nervous system sarcoma Diseases 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 229960002376 chymotrypsin Drugs 0.000 description 1
- 230000002860 competitive effect Effects 0.000 description 1
- 239000012531 culture fluid Substances 0.000 description 1
- 238000011266 cytolytic assay Methods 0.000 description 1
- 230000001461 cytolytic effect Effects 0.000 description 1
- 210000000805 cytoplasm Anatomy 0.000 description 1
- 230000001086 cytosolic effect Effects 0.000 description 1
- 238000002784 cytotoxicity assay Methods 0.000 description 1
- 231100000263 cytotoxicity test Toxicity 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 230000007123 defense Effects 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 230000006735 deficit Effects 0.000 description 1
- 239000003599 detergent Substances 0.000 description 1
- 238000002405 diagnostic procedure Methods 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 239000006196 drop Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 230000009977 dual effect Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 210000003722 extracellular fluid Anatomy 0.000 description 1
- 230000001605 fetal effect Effects 0.000 description 1
- GNBHRKFJIUUOQI-UHFFFAOYSA-N fluorescein Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 GNBHRKFJIUUOQI-UHFFFAOYSA-N 0.000 description 1
- 108020001507 fusion proteins Proteins 0.000 description 1
- 102000037865 fusion proteins Human genes 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 238000010353 genetic engineering Methods 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- -1 gp38-47 Proteins 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 208000019754 hemorrhagic gastroenteritis Diseases 0.000 description 1
- 238000009396 hybridization Methods 0.000 description 1
- 229910052588 hydroxylapatite Inorganic materials 0.000 description 1
- 229940124452 immunizing agent Drugs 0.000 description 1
- 230000001506 immunosuppresive effect Effects 0.000 description 1
- 239000003018 immunosuppressive agent Substances 0.000 description 1
- 229940124589 immunosuppressive drug Drugs 0.000 description 1
- 238000000099 in vitro assay Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 239000012678 infectious agent Substances 0.000 description 1
- 238000011081 inoculation Methods 0.000 description 1
- 239000002198 insoluble material Substances 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 238000007917 intracranial administration Methods 0.000 description 1
- 230000009602 intrauterine growth Effects 0.000 description 1
- 150000002540 isothiocyanates Chemical class 0.000 description 1
- 231100000518 lethal Toxicity 0.000 description 1
- 230000001665 lethal effect Effects 0.000 description 1
- 201000002364 leukopenia Diseases 0.000 description 1
- 231100001022 leukopenia Toxicity 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 210000004962 mammalian cell Anatomy 0.000 description 1
- 230000008774 maternal effect Effects 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 238000002483 medication Methods 0.000 description 1
- 108020004999 messenger RNA Proteins 0.000 description 1
- CXKWCBBOMKCUKX-UHFFFAOYSA-M methylene blue Chemical compound [Cl-].C1=CC(N(C)C)=CC2=[S+]C3=CC(N(C)C)=CC=C3N=C21 CXKWCBBOMKCUKX-UHFFFAOYSA-M 0.000 description 1
- 229960000907 methylthioninium chloride Drugs 0.000 description 1
- 208000004141 microcephaly Diseases 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 238000007479 molecular analysis Methods 0.000 description 1
- 230000004001 molecular interaction Effects 0.000 description 1
- 229940100662 nasal drops Drugs 0.000 description 1
- 230000000926 neurological effect Effects 0.000 description 1
- 201000001119 neuropathy Diseases 0.000 description 1
- 229920001220 nitrocellulos Polymers 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 231100000255 pathogenic effect Toxicity 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 230000000149 penetrating effect Effects 0.000 description 1
- 229940056360 penicillin g Drugs 0.000 description 1
- XYJRXVWERLGGKC-UHFFFAOYSA-D pentacalcium;hydroxide;triphosphate Chemical compound [OH-].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O XYJRXVWERLGGKC-UHFFFAOYSA-D 0.000 description 1
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 description 1
- 102000013415 peroxidase activity proteins Human genes 0.000 description 1
- 108040007629 peroxidase activity proteins Proteins 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 1
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 238000009117 preventive therapy Methods 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 238000000159 protein binding assay Methods 0.000 description 1
- 230000017854 proteolysis Effects 0.000 description 1
- 230000002797 proteolythic effect Effects 0.000 description 1
- 230000002285 radioactive effect Effects 0.000 description 1
- 238000000163 radioactive labelling Methods 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 230000004043 responsiveness Effects 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 210000003296 saliva Anatomy 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 238000005549 size reduction Methods 0.000 description 1
- 239000011537 solubilization buffer Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 230000008866 synergistic binding Effects 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 229940104230 thymidine Drugs 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- JLEXUIVKURIPFI-UHFFFAOYSA-N tris phosphate Chemical compound OP(O)(O)=O.OCC(N)(CO)CO JLEXUIVKURIPFI-UHFFFAOYSA-N 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
- 230000029812 viral genome replication Effects 0.000 description 1
- 230000003253 viricidal effect Effects 0.000 description 1
- 238000012800 visualization Methods 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
- C07K16/081—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from DNA viruses
- C07K16/085—Herpetoviridae, e.g. pseudorabies virus, Epstein-Barr virus
- C07K16/089—Cytomegalovirus
Definitions
- the present invention is directed to a number of pharmaceutical compositions suitable for diagnosis or therapeutic treatment of human cytomegalovirus (HCMV) infections, to methods of medical diagnosis and
- HCMV Human cytomegalovirus
- HCMV is the most common cause of congenital and opportunistic infections associated with acquired immune deficiency syndrome (AIDS) and with patients undergoing organ and bone marrow transplants. Rejection of graft material is also frequently associated with HCMV
- HCMV infection of a developing fetus may retard intrauterine growth and cause congenital
- HCMV infections in human immunodeficiency virus (H ⁇ V)-seropositive individuals result in such complications as chorioretinitis,
- HCMV hepatitis, hemorrhagic gastroenteritis, and progressive interstitial pneumonia.
- HCMV has been implicated in the pathogenesis of peripheral neuritis and progressive encephalomyelopathy associated with HIV infections of the central nervous system and Kaposi's sarcoma.
- HCMV has also been implicated as a co-factor in the development of overt AIDS by causing immunosuppression of high-risk HIV-seronegative individuals which
- HCMV-seronegative transplant recipients Exposure of HCMV-seronegative transplant recipients to HCMV-infected donor organs or blood products may result in symptomatic HCMV infections which lead to interstitial pneumonia, leukopenia,
- HCMV-seronegative blood products, organs and bone marrow significantly reduces the risk of HCMV infection.
- HCMV-seropositive donors cannot be excluded in all cases because of the limited supply of appropriately matched donor organs and bone marrow and the urgency of most heart and liver transplants.
- HCMV infection in seropositive transplant recipients is the consequence of their immunosuppressed condition in conjunction with the reactivation of latent HCMV virions.
- HCMV hyperimmune globulin Prophylactic administration of anti-viral chemotherapy or HCMV hyperimmune globulin or plasma prior to and following organ and bone marrow transplants has met with limited success.
- the reason is that HCMV hyperimmune globulin is active against extracellular HCMV present in the early stage of infection but may not be active against late stage intracellular virion replication and/or cell-to-cell spread.
- HCMV-hyperimmune globulin provides some protection for an HCMV-seronegative patient receiving bone marrow or an organ from an HCMV-seropositive donor, but has little effect in inhibiting the reactivation of latent
- HCMV has a slow replication cycle compared to that of other herpes viruses and is highly cell- associated which makes the virus relatively inaccessible to humoral antibodies.
- HCMV uses certain host cell enzymes for viral replication rather than virus- specific enzymes which can be interdicted by certain anti-viral drugs.
- HCMV hyperimmune globulin primarily contains antibodies directed at substances other than HCMV as well as antibodies that may protect the virus at the expense of the host. Therefore, with that treatment only a small proportion of the total antibody protein is effective against HCMV.
- a further disadvantage of human immune globulin preparations is its potential for transmitting infectious agents such as hepatitis or the human immunodeficiency virus (HIV).
- mcAb monoclonal antibody
- HCMV naturally occurring strains of HCMV or in cases where a patient is infected with multiple strains of HCMV. It can also be expected that a virus like HCMV will mutate into resistent strains in response to the prolonged administration of a single mcAb.
- Existing murine antibody therapies also present the risk that the patient will develop human anti-mouse antibodies (HAMA) in response to the therapeutic mcAb.
- HAMA human anti-mouse antibodies
- HCMV virus structure of the HCMV virus.
- the most abundant HCMV envelope glycoproteins and glycoprotein complexes are summarized in Table 1 shown below.
- glycoproteins The gCI family of glycoprotein complexes (gC) contains glycoproteins (gp) with molecular weights of 130,000 (gpl30), 93,000 (gp93), and 55,000 (gp55). These glycoproteins have been designated as gB glycoproteins based on extensive amino acid sequence homology with the gB glycoproteins of herpes simplex virus (HSV) and
- EBV Epstein-Barr virus
- VZV varicella zoster virus
- U L unique long
- gp55 and gp93 may represent the carboxy-terminal and amino-terminal components of a fully glycosylated precursor, respectively, resulting from a single proteolytic cleavage event.
- a third glycoprotein, gp130 may result from a minor
- glycoproteins exist in virion envelopes primarily in the form of disulfide-linked complexes.
- the glycoproteins gpl30 and gp55 were originally identified as gA by Pereira et al., and claimed in U.S. Patent No. 4,689,225, issued August 8, 1987, the disclosure of which is incorporated by
- gp93 has been identified as a
- glycoprotein unique from gp55 and gpl30 glycoprotein unique from gp55 and gpl30, and unique murine mcAbs reactive with gp93 have been described in pending U.S. Patent Application Serial No. 07/407,276, filed on September 14, 1989, the disclosure of which is incorporated by reference herein.
- the unreduced gCI complex with a molecular weight of 130,000 contains gpl30 and gp55
- the gCI complex with a molecular weight of 180,000 contains gpl30 and gp93
- glycoproteins glycoproteins
- a second family of glycoprotein complexes designated as gCII is comprised of an abundant glycoprotein of 47,000 - 52,000 (gp47-52) and a group of glycoproteins with molecular weights of 38,000-47,000, 90,000 and greater than 200,000.
- gp47-52 is the product of a bicistronic mRNA transcript encoded by the HXLF 1 and 2 genes of a homologous gene family in the Hind III F fragment of the unique short (U 8 ) region of the HCMV genome.
- the unreduced gCII complex with a molecular weight of 93,000 is comprised of multimer (a covalently bonded combination of several polymeric molecules) of a single glycoprotein, gp47-52, recognized by the family of mcAbs designated as Group 1 gCII mcAbs as claimed in U.S. Patent Application Serial No. 07/390,300, filed on August 7, 1989, the disclosure of which is incorporated by reference herein.
- unreduced gCII complex with a molecular weight of greater than 200,000 contains antigenically distinct glycoproteins gp38-47, gp90 and gp200, recognized by Group 2 gCII mcAbs claimed in U.S. Patent Application Serial No. 07/390,300, filed on August 7, 1989, the disclosure of which is incorporated by reference herein, as well as gp47-52 recognized by Group 1 mcAbs.
- the complex molecular organization of the HXLF gene family and the polymorphism of its related gCII glycoproteins suggest that HCMV has evolved these glycoproteins for some essential biological function.
- glycoproteins and glycoprotein complexes are important in maintaining the structural integrity of the virion, and also play an essential role in
- a goal of the present invention is the development of a pharmaceutical composition that can significantly reduce the incidence and severity of HCMV infections.
- a particular objective of the invention is the production of a pharmaceutical composition that is active against HCMV in both the extracellular phase or early stage of HCMV infection and the intracellular phase or late stage of HCMV infection.
- composition would be useful for treating individuals with established HCMV infections as well as for
- prophylaxis for those who are highly susceptible to HCMV infection. Yet another goal is the development of a composition which is active against virtually all strains of HCMV and will forestall the development of resistent strains of HCMV. A further goal is to develop a pharmaceutical composition active against HCMV which will reduce the risk of HAMA response in a patient.
- the cocktail composition which is suitable for both
- diagnostic and therapeutic use constitutes a mixture of at least two HCMV-specific immunoglobulins.
- the cocktail contains at least two anti-viral immunoglobulins each of which binds with a different segment of HCMV envelope glycoproteins or complexes. Preferably, these segments incorporate different, unique, non-competing epitopes on the same or different HCMV envelope glycoproteins. This function produces cocktail reactivity with multiple strains of HCMV.
- the cocktail contains at least two anti-viral immunoglobulins each of which binds with a different segment of HCMV envelope glycoproteins or complexes.
- these segments incorporate different, unique, non-competing epitopes on the same or different HCMV envelope glycoproteins. This function produces cocktail reactivity with multiple strains of HCMV.
- the mixture contains at least two anti-viral immunoglobulins each of which binds with a different segment of HCMV envelope glycoproteins or complexes.
- these segments incorporate different, unique, non-competing epitopes on the same or different HCMV envelope glycoproteins. This function produces cocktail re
- immunoglobulins at least in part, exhibit synergistic anti-viral neutralizing activity against HCMV and are active against different phases of HCMV infection.
- At least one of the immunoglobulins of the mixture will enhance the neutralizing activity of another member of the mixture and those or other members will exhibit complement-dependent and complement-independent anti-viral
- a preferred embodiment of the mixture combines three immunoglobulins, two being the synergistic pair of which one provides complement-dependent anti-viral activity, and the third providing complement-independent anti-viral activity.
- Another preferred embodiment of the mixture combines four immunoglobulins, two providing synergistic anti-viral activity against HCMV, a third exhibiting complement-dependent anti-viral activity, and a fourth providing complement-independent anti-viral activity.
- Immunoglobulins which are suitable for the composition of the invention include HCMV-specific antibodies such as murine monoclonal antibodies (mcAbs), immunogenic fragments thereof such as Fab, F(ab) 2 and their mixture with Fc, human monoclonal antibodies, chimeric antibodies carrying human constant regions, and altered human antibodies carrying hypervariable segments derived from HCMV-specific antibodies from a differing mammalian source.
- mcAbs murine monoclonal antibodies
- composition of the invention is the mixture of four murine mcAbs designated as MM-HCMV-9B7, MM-HCMV-41C2 , MM-HCMV-F15-3B10, and MM-HCMV-15F9 (In Vitro
- the cocktail composition When the cocktail composition is to be employed as a pharmaceutical composition for therapeutic and prophylactic treatment of HCMV infection in humans, it will be composed of a therapeutically effective amount of the foregoing immunoglobulin mixture with a pharmaceutically-acceptable carrier.
- the carrier is preferably a liquid.
- the cocktail composition When the cocktail composition is to be employed for diagnostic purposes such as in vitro analysis, it will be composed of appropriate diagnostic amounts of the foregoing immunoglobulin mixture, optional suitable diluents whether or not pharmaceutically acceptable and optionally, detection markers or tags for measurement of the amount of HCMV detected.
- the invention is further directed to a method of therapeutic and prophylactic medical treatment for HCMV infection which involves administering a
- the invention is also directed to a method of making the immunogenic cocktail composition which involves selecting compatible immunoglobulins which manifest certain predetermined activity against HCMV, and combining the immunoglobulins with a suitable carrier.
- a pharmaceutical composition a pharmaceutically-acceptable carrier is combined with the mixture.
- the carrier is a liquid.
- This cocktail provides a preparation useful for the treatment of early and/or late HCMV infections in humans caused by virtually all strains of HCMV.
- immunoglobulins useful in the mixture may be derived from various sources, the preferred type being monoclonal antibodies. Tables 2-8 outline
- antibodies for a particular mixture may be derived from hybridomas or other cell lines (i.e., EBV-transformed lymphoblastoid cell lines, transfected mammalian cell lines expressing immunoglobulin genes) that generate human, chimeric, bi-specific rearranged and murine antibodies.
- hybridomas or other cell lines i.e., EBV-transformed lymphoblastoid cell lines, transfected mammalian cell lines expressing immunoglobulin genes
- the unique specificity and functional activity of the murine HCMV-specific mcAbs in the cocktail have been precisely characterized and those structural features of the murine mcAbs that provide the specificity and activity can be engineered into chimeric human-mouse mcAbs exhibiting similar therapeutic
- hybridomas producing human antibodies of similar specificity can be obtained by immunizing and/or screening with purified HCMV peptides recognized by the murine mcAbs in the cocktail. Methods to prepare these antibodies have been previously
- F(ab) or F(ab') 2 fragments may be utilized alone or in combination with Fc fragments.
- F(ab) or F(ab') 2 fragments may be utilized alone or in combination with Fc fragments.
- the immunoglobulin members of the cocktail react with as many naturally occurring strains of HCMV as possible while exhibiting no cross- reactivity with other viruses or normal cellular
- the cocktail contain at least two different anti-viral agents.
- immunoglobulins that are reactive with unique, non- competing epitopes on the same or different HCMV
- the cocktail comprises an immunoglobulin mixture that exhibits specificity for multiple epitopes, augmenting activity, and synergistic anti-viral activity directed against mechanisms associated with both extracellular viral infection and established intracellular
- a single immunoglobulin may function in more than one capacity.
- a particular immunoglobulin is thus selected on the basis of its reactivity with specific epitopal sites on an HCMV glycoprotein complex or component glycoprotein, its synergistic activity in combination with other
- immunoglobulins its complement-dependent or complement- independent anti-viral activity against HCMV, and its activity against early stage extracellular HCMV or late stage intracellular HCMV.
- Immunoglobulins used in the cocktail are reactive with HCMV envelope glycoproteins. Since those glycoproteins are expressed on the surface of HCMV virions as well as on the membranes and in the cytoplasm of cells which have become infected with the virus, the preparation provides neutralizing activity against both extracellular and intracellular HCMV virions.
- the selection of a particular immunoglobulin depends on the type of anti-viral activity sought.
- the cocktail contains at least two HCMV- specific immunoglobulins that exhibit anti-viral
- the cocktail combine at least two monoclonal antibodies with different anti- viral activity selected from the following types of neutralizing actions:
- ADCC antibody-dependent cellular cytoxicity
- immunoglobulins are combined which react with different glycoprotein complexes (gC) and with different glycoproteins (gp) within those complexes.
- GC glycoprotein complexes
- gp glycoproteins
- glycoproteins and glycoprotein complexes are summarized in Table 1.
- the gCI-specific immunoglobulins include those which are reactive with glycoproteins with molecular weights of 130,000 (gpl30), 93,000 (gp93) and 55,000 (gp55).
- gpl30 glycoproteins with molecular weights of 130,000 (gpl30), 93,000 (gp93) and 55,000 (gp55).
- gp93 glycoproteins with molecular weights of 130,000 (gpl30), 93,000 (gp93) and 55,000 (gp55).
- gCI-specific mcAbs preferred are those outlined in Table 2 and Table 3, as shown below.
- the gCI- specific immunoglobulins include MM-HCMV-9B7, a gp55- specific neutralizing IgG 2b mcAb (deposit no. IVI-10117), MM-HCMV-41C2, a gp55-specific non-neutralizing IgGi mcAb (deposit no. IVI-10119), and MM-HCMV-F15-3B10, a gp93- specific neutralizing IgGi mcAb (deposit no. IVI-10207).
- MM refers to an internal code designation of the manufacturer, Medimorphics).
- an immunoglobulin specific to the gCII complex may inhibit HCMV adsorption and penetration of tissues, intracellular virion
- Immunoglobulins specific to the gCII complex include Group 1 gCII immunoglobulins which are reactive with gp47-52 and recognize membrane-associated glycoproteins, and Group 2 gCII immunoglobulins which are recognize gp38-47, gp90 and gp200 of gCII and exhibit activity against
- gCII-specific mcAbs preferred are those listed in Table 4, as shown below.
- Group 1 gCII-specific immunoglobulins include MM-HCMV-9E10, a gp47-52-specific neutralizing mcAb (deposit no. IVI- 10118), and MM-HCMV-8B4, MM-HCMV-8B2, and MM-HCMV-26E11, three gp47-52-specific non-neutralizing mcAbs.
- Group 2 gCII-specific immunoglobulins include, among others, MM- HCMV-15F9, a non-neutralizing mcAb specific to gp38-47, gp90 and gp200 (deposit no. IVI-10182).
- immunoglobulins specific to gp55 and gp93 of the gCI glycoprotein complexes are combined with
- immunoglobulins which react with gp38-47, gp90 and gp200 of the gCII complexes containing Group 2 glycoproteins.
- the antigen specificity and the anti-viral activity of such preferred mcAbs selected for the mixture of an
- HCMV-specific mcAb cocktail as summarized in Table 5 below.
- At least one immunoglobulin specific to the gCI glycoprotein complex of HCMV may be selected for its complement-dependent neutralizing activity.
- complement-dependent neutralization of HCMV may involve extracellular lysis of virions.
- this condition may involve extracellular lysis of virions.
- neutralizing activity is directed against a complement-dependent epitope of gp55 of the gCI glycoprotein complexes.
- MM-HCMV-39E11 MM-HCMV- 18F9
- MM-HCMV-9B7 MM-HCMV-9B7
- MM-HCMV- 9B7 a murine IgG 2b mcAb (deposit no. IVI-10117), can be selected for the mixture for its complement-dependent neutralizing activity with an epitope on gp55.
- At least one immunoglobulin which exhibits complement-independent neutralizing activity toward the gCI glycoprotein complexes of HCMV may also be selected for the mixture. This activity may interfere with HCMV infectivity by blocking adsorption to viral receptors expressed on target organs and by preventing the
- MM-HCMV-3C2 MM- HCMV-9F9
- MM-HCMV-F15-3B10 MM-HCMV-F15-3B10
- an embodiment of the invention can include MM-HCMV-F15- 3B10, a murine IgG 1 mcAb.
- At least one immunoglobulin may be incorporated into the mixture based on its reactivity against Group 2 glycoproteins in gcll glycoprotein complexes of HCMV. Reactivity against gCII glycoprotein complexes may interfere with late stage intracellular HCMV by
- Table 4 outlines Group 2 gCII mcAbs which are among those preferred for this activity.
- mcAb is MM-HCMV-15F9, a murine IgG 2a mcAb (deposit no. IVI-10182) which is reactive with gp38-47, gp90 and gp200 of the gCII glycoprotein complexes containing Group 2 glycoproteins.
- At least one immunoglobulin is selected to inactivate extracellular HCMV associated with the early stage of infection and at least one immunoglobulin is selected to inhibit intracellular HCMV once infection of tissues has occurred.
- early stage antiviral activity against HCMV is provided by gCI- specific immunoglobulins with complement-dependent and complement-independent neutralizing activity while late stage inhibitory activity against intracellular HCMV is provided by Group 2 gCII-specific immunoglobulins.
- gCI-specific immunoglobulins with complement-dependent and complement-independent neutralizing activity
- late stage inhibitory activity against intracellular HCMV is provided by Group 2 gCII-specific immunoglobulins.
- glycoprotein complex of HCMV can provide complement- dependent neutralization which involves extracellular lysis of HCMV virions.
- MM-HCMV-F15-3B10 a complement- independent murine IgGj mcAb specific to gp93 of the gCI complex, may also interfere with early stage exogenous
- the Group 2 gCII-specific murine IgG 2a mcAb MM-HCMV-15F9 may inhibit intracellular virion assembly and/or cell-to-cell spread of HCMV.
- At least two immunoglobulins are selected because of their synergistic enhancement of neutralizing activity against HCMV that occurs when the
- immunoglobulins are combined. It is preferred that the immunoglobulins are reactive with unique, augmenting epitopes on the same or different HCMV envelope
- glycoproteins such that the anti-viral activity of the immunoglobulins in combination is substantially greater than the sum of the activities of each immunoglobulin acting alone.
- the augmenting activity may result from the molecular interactions between immunoglobulins reactive with epitopes in close spatial proximity on the conformational structure of a single glycoprotein or from interactions between immunoglobulins directed against different glycoproteins. It is preferred that at least one immunoglobulin react with a non- neutralizing epitope to cause conformational changes in the three-dimensional structure of the glycoprotein which in turn increases the accessibility of the second immunoglobulin toward a neutralizing epitope.
- the neutralizing activity is directed at a complement-dependent epitope of the gCI glycoprotein complexes.
- the result of the combined activity of the immunoglobulins is an increase in the complement- dependent activity of the neutralizing immunoglobulin.
- This synergistic activity may be provided by combining mcAbs specific to Domain I of the gCI
- an embodiment providing this activity may be two mcAbs specific to gp55 on the gCI glycoprotein complexes of HCMV. These mcAbs are selected for their synergistic
- MM-HCMV-41C2 a murine IgG 1 mcAb (deposit no. IVI-10119)
- MM-HCMV-9B7 a murine IgG 1 mcAb
- IVI-10119 can be selected for its non-neutralizing activity with an epitope located in close spatial proximity on the conformational structure to the epitope recognized by MM-HCMV-9B7 in order to augment the complement-dependent neutralizing activity of MM-HCMV-9B7 and enhance extracellular lysis of HCMV virions.
- Representative sources of monoclonal antibodies reactive with HCMV envelope glycoprotains are provided in Tables 6 and 7 shown below.
- Hybridomas producing HCMV-specific mcAbs that are deposited at ln Vitro International, Inc. are listed in Table 8 shown below.
- the cocktail can be achieved by mixing the mcAbs in different proportions and combining the mixture with the carrier. It is preferred that a range of ratios and immunoglobulin concentrations of various combinations of
- immunoglobulins be evaluated according to
- microneutralization assay and the proportion of a mcAb member within the mixture be selected from the
- ranges of 100:1 to 1:100 be evaluated.
- a 10-100 fold increase in the neutralizing activity has been observed in 9B7:41C2 over a range of 1:10 to 1:500, in 41C2:34G7 over a range of 1:20 to 1:200, and in 34G7:41C2 over a range of 1:10 to 1:1000.
- the three mcAbs that exhibit unique specificity and anti-viral activity directed at different HCMV glycoproteins be combined in equimolar ratios within a range of 100:1 to 1:100 for all components.
- the ratio of the embodiment MM-HCMV-9B7: MM-HCMV-F15-3B10: MM-HCMV-15F9 is 1:1:1. It is further preferred that the pair of augmenting gCI-specific mcAbs, in particular MM-HCMV-9B7:MM-HCMV-41C2, are combined in a ratio within a range of 100:1 to 1:100 depending on the optimal ratio that will achieve maximum synergistic anti-viral activity of the two mcAbs alone and in combination with other mcAbs in the cocktail.
- the invention also provides for use of the cocktail composition for in vitro detection of HCMV infection.
- the synergistic binding activity of a combination of immunoglobulins in the cocktail is also provided.
- composition can be used to increase the sensitivity of detection of extracellular HCMV virions in clinical specimens (i.e., urine, saliva, bronchoalveolar lavage fluid) and HCMV transplant organs, blood products, or biopsy/autopsy specimens over any single immunoglobulin.
- clinical specimens i.e., urine, saliva, bronchoalveolar lavage fluid
- HCMV transplant organs i.e., blood products, or biopsy/autopsy specimens over any single immunoglobulin.
- the combination of a primary immunoglobulin labeled with a suitable detection molecule together with one or more augmenting immunoglobulins which increase the binding of the primary antibody to its target antigen can be used in any immunoassay format, including radioimmunoassay (RIA), enzyme-linked immunosorbant assay (ELISA), or immunofluorescence (IF) to increase the sensitivity of detecting HCMV virions and glycoproteins.
- RIA radioimmunoassay
- ELISA enzyme-
- the invention also provides for a
- composition comprising an amount of the immunoglobulin mixture which is effective to inhibit HCMV infectivity in a patient, when administered
- composition is useful for treating patients with established HCMV infection and for
- the carrier of the pharmaceutical composition may be any material which is otherwise inert, medically- acceptable and compatible with the active ingredients of the composition, and which assists in administering the immunoglobulin mixture to the patient.
- the carrier may be comprised of a physiologically balanced salt
- the carrier may
- buffers include buffers, extenders, solubilizing agents, stabilizing agents, and the like.
- the pharmaceutical composition can be formulated as a powder, granules, solution, dispersion, aerosol, powder, or drops.
- the solution may be sterile, isotonic, and suitable for parenteral administration by intravenous, intramuscular, intraperitoneal, or
- the solution may contain appropriate adjuvants, buffers, preservatives and salts.
- the solution is preferably aqueous.
- the powder or granular forms may be combined with a solution and with diluting, dispersing and/or surface active agents.
- Solutions such as nose drops may contain antoxidants, buffers and the like.
- the invention further provides for methods of medical treatment of HCMV infection utilizing the pharmaceutical preparation of the immunoglobulin
- the cocktail composition may be administered to organ and bone marrow transplant recipients, HIV- seropositive patients, pregnant women exposed to or infected with HCMV in order to prevent symptomatic congenital HCMV infection of the developing fetus, and other high-risk individuals. Another method of
- treatment entails therapeutic intravenous
- HCMV infections including HCMV-seropositive patients and those with acquired immune deficiency (AIDS) and HCMV infections.
- AIDS acquired immune deficiency
- composition to be administered to a patient the composition to be administered to a patient
- composition may typically be administered in a single dose or in multiple doses at effective non-toxic dose levels of about 1 mg/kg/day of the cocktail per body weight, based on a half-life of at least eight hours and non-synergistic anti-viral activity by the cocktail.
- ln vitro comparisons show the activity of the cocktail combination of mcAbs at a level of more than 100 times that of HCMV hyperimmune globulin. This increased activity derives from combining only HCMV-specific mcAbs in the preparation and from including in the mixture immunoglobulins which synergistically immunoreact to augment the activity of a neutralizing mcAb. Where synergistic activity is demonstrated in vivo, either the quantity of mcAb cocktail administered per dose may be reduced or the interval between doses may be increased.
- the pharmaceutical composition may be administered rectally, vaginally, ocularly, nasally, intravenously, intramuscularly, intraperitoneally, or subcutaneously.
- a composition composed of a mixture of HCMV- specific monoclonal immunoglobulins has several
- hyperimmune globulin medications Those treatments have met with limited success due to the nature of HCMV and its different phases of infection, that is its early extracellular phase and its late stage intracellular phase. Moreover, the occurrence of multiple strains and mutated forms of HCMV limits the therapeutic effect of administering preparations comprised of a single
- cocktail composition activity against HCMV is extended from a single phase of HCMV infection to several phases.
- HCMV has a slow replication cycle compared to that of other herpes viruses and is highly cell-associated, making HCMV relatively inaccessible to humoral antibodies.
- HCMV uses certain host cell enzymes for its replication rather than virus-specific enzymes which are involved in the activity of some antiviral drugs.
- the invention combines together multiple immunoglobulins which are directed at different phases of HCMV infection, namely the extracellular phase which is associated with the early stages of infection and the intracellular phase which occurs in the late stages of actual infection of tissues .
- This feature of the anti- HCMV immunoglobulin cocktail makes the preparation useful for treating individuals with established HCMV infections by inhibiting spread of HCMV in the
- Sera from patients recovering from HCMV infection have been shown to contain antibodies reactive with gp55, gp93 and gpl30 of the gCI complex of HCMV, and with Group 1 and Group 2 glycoproteins in gCII complexes.
- sera obtained from infants with symptomatic congenital HCMV infection and their mothers showed reactivity with gpl30, gp55 and gp93 of the gCI glycoprotein complex but not with either Group 1 or Group 2 gCII glycoproteins.
- the presence of gCI- specific antibodies in the sera of both groups of patients suggests that antibodies specific to the gCI glycoprotein complex may not be sufficient for recovery from persistent HCMV infection.
- the present invention provides an improvement over existing preparations directed at established HCMV infections because it combines both gCI-specific and gCII-specific immunoglobulins into the cocktail composition.
- the multi-immunoglobulin cocktail of the present invention also provides activity against multiple strains of HCMV and decreases the incidence of resistant strains of HCMV which are likely to emerge during prolonged administration of a single HCMV
- the mcAb cocktail provides activity not only against multiple strains of HCMV but virtually all naturally occurring strains of HCMV. As such the cocktail provides an improvement over existing preparations because it will be useful in treating all immunosuppressed patients, irrespective of how many strains of HCMV are present.
- in vitro propagation of HCMV in the presence of particular mcAbs has resulted in mcAb-resistant (mar)-mutant viruses which have selectively deleted the epitope recognized by that particular antibody.
- the cocktail composition of the invention is a distinct advantage over single mcAb formulations by virtue of the mixture which, because of its reactivity with unique epitopes of the HCMV envelope glycoprotein, virtually eliminates the possibility of HCMV viral resistance.
- a further advantage of the composition of the invention is its increased level of activity against HCMV as compared to existing therapies.
- High-risk patients such as organ and bone marrow transplant recipients, patients with congenital or acquired immune deficiency diseases, and patients receiving immunosuppressive drugs frequently develop life- threatening opportunistic HCMV infections which are unresponsive to currently available anti-viral drugs and HCMV-hyperimmune globulin.
- In vitro assays show a level of activity in the cocktail composition of 100 times that of HCMV hyperimmune globulin. As a result of this enhanced activity, the quantity of monoclonal antibody protein required to achieve a desired anti-viral effect is reduced, thereby decreasing the amount and/or
- the increased level of activity of the composition of the invention stems in part from its make-up.
- the cocktail composition is comprised exclusively of HCMV-specific mcAbs.
- the cocktail preparation is a distinct advantage over existing preparations because it is able to provide HCMV-specific antibodies in plasma and interstitial fluid at a level sufficient to inactivate HCMV as an exogenous virion and as an intracellular replicating virion.
- the heightened activity of the cocktail is also a result of the synergism that occurs between certain members of the immunoglobulin mixture whereby the binding and neutralizing activity of at least one of the members is augmented.
- the total amount of immunoglobulin (Ig) protein which must be administered to attain a
- HAMA human anti-mouse antibody
- the composition of the present invention provides an advantage over existing preparations.
- the anti-isotypic HAMA response to the mcAb cocktail combination is likely to be comparable to that of an equivalent amount of a single mcAb.
- the human antibody response to four different idiotypic determinants on the hypervariable regions of F(ab) regions of the four mcAbs in the cocktail may be reduced as compared to the response to a larger quantity of a single HCMV-specific mcAb that expresses a single idiotope. Since anti-idiotypic antibodies are more likely to interfere with the biologically active sites on the therapeutic mcAb, a reduction in that HAMA response represents a significant advantage to the mcAb cocktail composition.
- the cocktail of the present invention is especially effective in diagnosing and detecting the presence of HCMV in patients, transplant material, and blood products.
- mcAbs that are active against different glycoproteins expressed by virtually all strains of HCMV
- in vitro detection of HCMV virions is greatly enhanced over single HCMV-specific mcAb preparations.
- the increased sensitivity of the cocktail ensures that its use in a diagnostic test will provide detection of all strains of HCMV.
- both extracellular virions in clinical samples and HCMV glycoproteins expressed on the surface of infected tissues will be detected by the cocktail composition.
- Monoclonal antibodies were generated by using purified Towne HCMV virions as the immunizing antigen.
- Adult BALB/c mice were immunized intraperitoneally with antigen emulsified in complete Freund's adjuvant, followed with three booster immunizations using saline- suspended immunogen given at three-week intervals.
- the mouse was sacrificed and the spleen cells fused with SP2/0 - Ag14 myeloma cells (American Tissue Culture Collection) at a ratio of 4:1 using polyethylene glycol. Twenty-four hours later, the fused cells were distributed into 96 wells in Hepes-buffered Dulbecco's modified Eagle's medium (DMEM) supplemented with 10% fetal bovine serum, 50 ug/ml garamycin, 13.6 ug/ml hypoxanthine, 0.4 r ⁇ aminopterin and 7.6 ug/ml thymidine. After two weeks in this medium, the cells were transferred to new medium supplemented as above but without aminopterin.
- DMEM Hepes-buffered Dulbecco's modified Eagle's medium
- gCI complex was immunoaffinity purified from a non-ionic detergent extract of HCMV using a gp55- specific biotinylated mcAb and streptavidin-agarose according to Gretch et al., Anal. Biochem. 163:270-277 (1987).
- the gCI complex was reduced and separated by SDS-PAGE in a 9% polyacrylamide gel using the method of Laemmli, Nature 227:680-684 (1970). Proteins were detected by Commassie blue staining and the gp93 band was cut from the polyacrylamide gel.
- the glycoprotein was electroeluted from the gel slice and SDS was removed from the protein with a 0.5 ml column of Extracti-gel D (Pierce Chemical Co.). Mice were immunized with
- mice were immunized with 100 ug of whole Towne strain HCMV emulsified in complete Freund adjuvant and given a booster immunization with 100 ug whole Towne HCMV at three weeks. After several weeks a final boost was given using 20 ug of gCII which was purified by anion exchange high performance liquid chromatography according to Kari et al., (1986). Three days following the final boost with gCII, the mice were sacrificed and the spleen cells were fused with Sp2-0- Agl4 myeloma cells. Cloning was done according to Kari et al. (1986).
- culture medium was assayed for antibody against gCII by enzyme linked immunosorbant assay.
- purified gCII was fixed in 96 well dishes.
- Hybridomas were subcloned twice by limited dilution. All mcAbs used in these studies were subtyped and found to have a single subtype. Clonality was further assayed by agarose isoelectric focusing of purified mcAbs. Purification of monoclonal antibodies
- Monoclonal antibody from ascites was purified by high-performance hydroxylapatite chromatography, according to Juarez-Salinas et al., Biotechniques
- Glycoproteins were radiolabeled with [ 14 C]GlcN or [ 3 H]Arg (New England Nuclear) according to Kari et al. (1986). Labeled proteins were extracted from either extracellular virus or from infected whole cells using a Tris buffer (50mM Tris, pH 7.5, 150 mM NaCl, ImM
- Reactivity of the mcAbs with wild type and laboratory adapted strains (Towne, AD169, Toledo) of HCMV and several unrelated viruses was determined in an indirect immunofluorescence assay.
- Adenovirus, HSV, VZV, and wild type strains of HCMV were obtained from clinical isolates.
- immunofluorescence virus- infected and uninfected skin fibroblast cultures on glass slides were fixed in cold acetone:methanol (v/v, 1:1). Fixed cultures were preincubated with normal porcine serum and washed with phosphate-buffered saline (PBS). All subsequent steps were done with PBS
- FITC isothiocyanate
- hydroxylapatite HPLC were diluted in DMEM supplemented with 2% fetal bovine serum (FBS). Prior to infection, 600 plaque-forming units (pfu) of Towne and 300 pfu of Toledo strain HCMV were added to mcAb in a total volume of 0.4 ml of DMEM. Guinea pig complement (Pel-Freeze Biologicals, Rogers, Arkansas) was added to a final concentration of 2.0% in half the preparations; the remaining half received an equivalent volume of DMEM. Viral neutralization was allowed to proceed for 60 minutes at 37°C.
- FBS fetal bovine serum
- the HCMV-mcAb mixture was added to confluent layers of skin fibroblasts in 6-well plates (Costar, Cambridge, Massachusetts) and incubated for another 60 minutes for the virus to adsorb.
- the virus mixture was aspirated and 5 ml of DMEM supplemented with
- OD 490 was read.
- the biotinylated antibody was titered beforehand to determine the amount of antibody needed to give an OD 490 of 0.5 to 1.0 in the absence of a second unlabeled antibody. This assay was performed in
- glycoproteins comprising the gCI and gCII complexes
- Complement-dependent and -independent neutralizing HCMV-specific mcAbs that are reactive with gpl30 and gp55 have been obtained, and mcAbs reactive with unique epitopes on gpl30 and gp93 have been
- a simultaneous competitive ELISA assay has been used to identify eight gCI-specific mcAbs reactive with unique continuous or conformation- dependent epitopes in three domains comprising a major B-cell antigenic region of gp55 in gCI complexes, which is the subject of U.S. Patent Application Serial No.
- At least one gCII-specific mcAb has been described which variably exhibits complement-independent neutralizing activity against Towne strain HCMV and which has been shown to recognize an epitope uniquely expressed on gp47-52 of gCII complexes, as claimed in U.S. Patent Application Serial No. 06/933,789, filed on November 24, 1986, the disclosure of which is
- Antibodies that are directed against gCII glycoproteins are likely to inhibit virion adsorption and penetration, virion assembly, and/or cell-to-cell spread.
- Sera from patients who recover from HCMV infection contain antibodies reactive with structural virion proteins and glycoproteins and which exhibit neutralizing activity in the presence or absence of complement in vitro. Convalescent sera were examined by immunoprecipitation or Western blot analysis using HCMV- infected cell lysates or whole virions as antigens.
- gCII-specific antibodies were detected in sera taken from fraternal twins, one with asymptomatic congenital infection and the other with an HCMV infection acquired at six months of age. These data indicate that susceptibility to the pathogenic effects of HCMV may be associated with maternal/fetal non-responsiveness to gCII and that gCII- specific antibodies play an essential role in host defense. The presence of gCI-specific antibodies in all sera from congenitally-infected infants, and in
- monoclonal antibodies comprising the monoclonal antibody cocktail
- the gp55 (gCI)-specific mcAb MM-HCMV-9B7 was selected because it exhibits complement-dependent neutralizing activity in vitro, and can inactivate infectious virus during the extracellular phase of HCMV viremia associated with primary and reactivated HCMV infection.
- a second gp55 (gCI)-specific mcAb, MM-HCMV- 41C2 was included because it recognizes an epitope on gp55 in close spatial proximity on the conformational structure to the epitope recognized by mcAb 9B7 and can augment the binding and neutralizing activity of the 9B7 neutralizing mcAb to increase the therapeutic
- a third gCI-specific mcAb, MM-HCMV-F15-3B10 recognizes a complement- independent epitope on gp93, and can interfere with viral infectivity (i.e., block adsorption to the viral receptor expressed on target organs, prevent penetration of the virus into susceptible cells).
- Monoclonal antibody MM-HCMV-15F9 recognizes Group 2 gCII
- glycoproteins may prevent virion assembly and/or cell-to-cell spread which makes this mcAb useful for treating established intracellular infection.
- MM-HCMV-41C2 and MM-HCMV-F15-3B10 are IgG 1 mcAbs; MM-HCMV-9B7 is an IgG 2b mcAb; MM-HCMV-15F9 is an IgG 2a mcAb. Monoclonality was confirmed by isoelectric focusing.
- HCMV HCMV
- All mcAbs were tested for reactivity with HCMV (glyco)proteins expressed in fibroblasts infected with several strains of HCMV, including laboratory adapted strains (Towne, AD169, Toledo), 8 wild strain isolates obtained from infants with congenital HCMV infection or adults with opportunistic HCMV infections, and several unrelated viruses including herpes simplex virus (HSV) 1 and 2, varicella zoster virus (VZV), and adenoviruses types 2 and 5. All four mcAbs were reactive with the three laboratory adapted strains and eight wild strains of HCMV, but did not show cross-reactivity with proteins expressed in cells infected with HSV, VZV, or
- adenoviruses types 2 and 5 as determined by indirect immunofluorescence.
- all four mcAbs were tested for reactivity with a panel of cell lines of fibroblast, epithelial, and lymphoid origin, and with tissue sections from 10 different organs derived at autopsy. No reactivity was observed which confirmed that the mcAbs were not cross-reactive with normal cellular proteins.
- the gp93-specific mcAbs 3B10 also immunoprecipitated unreduced gCI complexes, and reacted with constituent glycoproteins gpl30 and gp93 in Western blot analysis.
- the gCII-specific mcAb 15F9 immunoprecipitated unreduced gCII complexes, and reacted with Group 2 gCII glycoproteins, gp38-47, gp90 and gp200 in Western blot analysis. 15F9 recognized perinuclear and cytoplasmic proteins in cells infected with Towne and AD169 strains of HCMV.
- the neutralizing activity of the four mcAbs was examined in a quantitative plaque reduction assay using both Towne and AD169 strains of HCMV.
- gp55-specific mcAb 9B7 neutralized both strains in the presence of complement, whereas gp55-specific mcAb 41C2 was non- neutralizing.
- gp93-specific mcAb 3B10 neutralized Towne and AD169 strains of HCMV in the absence of complement.
- Monoclonal antibody 15F9 was non-neutralizing in the plaque reduction assay.
- Monoclonal antibody 9B7 Monoclonal antibody 9B7
- microneutralization assays to determine reduction of plaque size as a reflection of inhibition of cell-to- cell spread, quantitative plaque inhibition as a
- Assays may be used to determine the potential anti-viral activity of HCMV-specific mcAbs but the extent to which this data may be extrapolated in order to define their protective activity in a human host is not yet determined.
- In vitro neutralization assays may be performed by pre-incubating virus with antibody in the presence or absence of complement, followed by washing and inoculation of a cell culture system in the absence of the antibody to determine if there is any residual infectious virus. Indications are that complement-dependent neutralization involves physical destruction of the virion whereas complement-independent neutralization involves selective blocking of a protein essential to the infectivity of the virus.
- Complement- independent neutralization may include such activity as an antibody which blocks access of a virion envelope glycoprotein to a cellular receptor wherein adsorption is prevented, or an antibody which blocks a fusion protein wherein an infectious virus is stopped from penetrating host cells.
- Molecular analysis of the gene encoding the gCI glycoproteins indicates that the glycoproteins performing those functions may be the analogue of a glycoprotein in herpes simplex virus which is involved in viral fusion.
- Additional assays can be utilized to determine whether non-neutralizing mcAbs exhibit virostatic antiviral activity; that is, whether a virus is non- infectious in the presence of the antibody but
- inhibitory antibodies may be as effective as those which are virocidal (i.e., lethal to the virus).
- Plaque size reduction assays indicate that gcll glycoproteins and complexes may play a critical role in virion assembly and/or cell-to-cell spread. Viral inhibition assays are thereby conducted to determine the capacity of the gcll- specific mcAbs (i.e., 15F9) to prevent cytopathogenicity in cell culture when continually present.
- Formulation of Pharmaceutical Cocktail The formulation of the pharmaceutical cocktail is determined on the basis of in vitro reactivity of the mcAbs with multiple strains of HCMV.
- formulations of the cocktail can be made by combining the four mcAbs in different proportions. Different dilutions of these combinations can be evaluated in a quantitative plaque reduction assay using Towne strain HCMV and in microneutralization, viral inhibition, and cytolytic assays to confirm anti-viral activity against multiple strains of HCMV.
- Cells/tissues obtained from patients or from prospective transplant material or blood products can be examined in vitro for evidence of HCMV glycoproteins.
- Seropositive tissues and/or sera can then be examined for sensitivity to different concentrations of various mcAbs mixtures according to in vitro anti-viral assays.
- the appropriate mixture of mcAbs as determined by the in vitro neutralization assays, can then be combined with a sterile aqueous solution containing a concentration of salt to achieve the physiological concentration found in human plasma, or with a
- physiologically balanced salt solution containing protein i.e., albumin
- protein i.e., albumin
- the total concentration of protein including mcAb protein does not exceed the normal protein concentration in human plasma (i.e., 5 gm/100 ml.).
- hybridomas were subcloned at least two times by limiting dilution to ensure clonality, and were shown to stably produce HCMV-specific antibody at a level of greater than 5 mg/ml in mouse ascites. All biological and immunological characterization of these mcAbs were performed on purified IgG obtained from HPLC hydroxyl apatite chromatography.
- component murine HCMV-specific mcAbs in the cocktail can be engineered into "humanized" mcAbs according to established methods including human-mouse B cell heterohybridomas, human-human B cell hybridomas, B lymphoblastoid cell lines by EBV transformation, and transfeetomas producing chimeric human-mouse
- variable region genes derived from murine hybridomas producing mcAbs of identical specificity with human constant region immunoglobulin genes or by
- immunoglobulin molecules are bivalent, a chimeric immunoglobulin molecule can be generated exhibiting dual specificity (two sites each of which bind a different epitope).
- anti-viral activity of certain mcAbs may reside in the variable region so that Fab or F(ab') 2 fragments may be used rather than whole immunoglobulin.
- Other mcAbs may require functional
Abstract
Disclosed is a pharmaceutical composition and a method for its use in the diagnosis and medical treatment of human cytomegalovirus infection. The immunogenic cocktail composition combines a mixture of at least two HCMV-specific immunoglobulins with a suitable carrier.
Description
HUMAN CYTOMEGALOVIRUS-SPECIFIC
MONOCLONAL ANTIBODY COCKTAIL
Field of Invention
The present invention is directed to a number of pharmaceutical compositions suitable for diagnosis or therapeutic treatment of human cytomegalovirus (HCMV) infections, to methods of medical diagnosis and
treatment of HCMV infections, and to a method of making compositions utilized in connection with HCMV infection.
Background of the Invention
Human cytomegalovirus (HCMV) is a ubiquitous virus and measures to limit exposure to HCMV have had little impact on the incidence or severity of congenital or opportunistic HCMV infections. A large number of asymptomatic HCMV-infected children and adults are known to episodically excrete HCMV in their body secretions and there is no known practical way to limit contact between them and individuals who are highly susceptible to HCMV infection, such as seronegative pregnant women and immunosuppressed patients.
HCMV is the most common cause of congenital and opportunistic infections associated with acquired immune deficiency syndrome (AIDS) and with patients undergoing organ and bone marrow transplants. Rejection of graft material is also frequently associated with HCMV
infection. HCMV infection of a developing fetus may retard intrauterine growth and cause congenital
complications such as chorioretinitis, microcephaly, intracranial calcifications, psychomotor retardation and multiple neurological defects. HCMV infections in human immunodeficiency virus (HΙV)-seropositive individuals result in such complications as chorioretinitis,
hepatitis, hemorrhagic gastroenteritis, and progressive interstitial pneumonia. HCMV has been implicated in the pathogenesis of peripheral neuritis and progressive encephalomyelopathy associated with HIV infections of the central nervous system and Kaposi's sarcoma. HCMV has also been implicated as a co-factor in the
development of overt AIDS by causing immunosuppression of high-risk HIV-seronegative individuals which
predisposes them either to primary HIV infection or to reactivation of latent HIV, or by providing
complimentary genetic information that increases the replication of HIV in cells which are co-infected with HCMV.
Exposure of HCMV-seronegative transplant recipients to HCMV-infected donor organs or blood products may result in symptomatic HCMV infections which lead to interstitial pneumonia, leukopenia,
chorioretinitis and other life-threatening
complications. The use of HCMV-seronegative blood products, organs and bone marrow significantly reduces the risk of HCMV infection. However, HCMV-seropositive donors cannot be excluded in all cases because of the limited supply of appropriately matched donor organs and bone marrow and the urgency of most heart and liver transplants. HCMV infection in seropositive transplant recipients is the consequence of their immunosuppressed condition in conjunction with the reactivation of latent HCMV virions.
Prophylactic administration of anti-viral chemotherapy or HCMV hyperimmune globulin or plasma prior to and following organ and bone marrow transplants has met with limited success. The reason is that HCMV hyperimmune globulin is active against extracellular HCMV present in the early stage of infection but may not be active against late stage intracellular virion replication and/or cell-to-cell spread. As a result, HCMV-hyperimmune globulin provides some protection for an HCMV-seronegative patient receiving bone marrow or an organ from an HCMV-seropositive donor, but has little effect in inhibiting the reactivation of latent
intracellular virions in HCMV-seropositive individuals.
Existing treatments of patients with
established HCMV infections have also had limited
success. HCMV has a slow replication cycle compared to that of other herpes viruses and is highly cell- associated which makes the virus relatively inaccessible to humoral antibodies. Moreover, HCMV uses certain host cell enzymes for viral replication rather than virus- specific enzymes which can be interdicted by certain anti-viral drugs. HCMV hyperimmune globulin primarily contains antibodies directed at substances other than HCMV as well as antibodies that may protect the virus at the expense of the host. Therefore, with that treatment only a small proportion of the total antibody protein is effective against HCMV. A further disadvantage of human immune globulin preparations is its potential for transmitting infectious agents such as hepatitis or the human immunodeficiency virus (HIV). Likewise, the administration of a single type of monoclonal antibody (mcAb) is not necessarily effective against all
naturally occurring strains of HCMV or in cases where a patient is infected with multiple strains of HCMV. It can also be expected that a virus like HCMV will mutate into resistent strains in response to the prolonged administration of a single mcAb. Existing murine antibody therapies also present the risk that the patient will develop human anti-mouse antibodies (HAMA) in response to the therapeutic mcAb.
In order to identify effective treatments against HCMV, it is important to understand the
structure of the HCMV virus. The most abundant HCMV envelope glycoproteins and glycoprotein complexes are summarized in Table 1 shown below.
The gCI family of glycoprotein complexes (gC) contains glycoproteins (gp) with molecular weights of 130,000 (gpl30), 93,000 (gp93), and 55,000 (gp55). These glycoproteins have been designated as gB glycoproteins based on extensive amino acid sequence homology with the gB glycoproteins of herpes simplex virus (HSV) and
Epstein-Barr virus (EBV), and gCII of varicella zoster virus (VZV). These glycoproteins derive from a single coding region in the unique long (UL) region of the HCMV genome, which may represent a primordial gene conserved among herpes viruses involved in biological functions critical to the evolution and survival of these viruses. Two mature glycoproteins, gp55 and gp93, may represent the carboxy-terminal and amino-terminal components of a fully glycosylated precursor, respectively, resulting from a single proteolytic cleavage event. A third glycoprotein, gp130, may result from a minor
carbohydrate modification of the precursor without proteolysis. These glycoproteins exist in virion envelopes primarily in the form of disulfide-linked complexes. The glycoproteins gpl30 and gp55 were originally identified as gA by Pereira et al., and claimed in U.S. Patent No. 4,689,225, issued August 8, 1987, the disclosure of which is incorporated by
reference herein. gp93 has been identified as a
glycoprotein unique from gp55 and gpl30, and unique murine mcAbs reactive with gp93 have been described in pending U.S. Patent Application Serial No. 07/407,276, filed on September 14, 1989, the disclosure of which is incorporated by reference herein. The unreduced gCI complex with a molecular weight of 130,000 contains gpl30 and gp55, the gCI complex with a molecular weight of 180,000 contains gpl30 and gp93, and the high
molecular weight gCI complexes contain all three
glycoproteins.
A second family of glycoprotein complexes designated as gCII is comprised of an abundant
glycoprotein of 47,000 - 52,000 (gp47-52) and a group of glycoproteins with molecular weights of 38,000-47,000, 90,000 and greater than 200,000. gp47-52 is the product of a bicistronic mRNA transcript encoded by the HXLF 1 and 2 genes of a homologous gene family in the Hind III F fragment of the unique short (U8) region of the HCMV genome. The unreduced gCII complex with a molecular weight of 93,000 is comprised of multimer (a covalently bonded combination of several polymeric molecules) of a single glycoprotein, gp47-52, recognized by the family of mcAbs designated as Group 1 gCII mcAbs as claimed in U.S. Patent Application Serial No. 07/390,300, filed on August 7, 1989, the disclosure of which is incorporated by reference herein. A higher molecular weight
unreduced gCII complex with a molecular weight of greater than 200,000 contains antigenically distinct glycoproteins gp38-47, gp90 and gp200, recognized by Group 2 gCII mcAbs claimed in U.S. Patent Application Serial No. 07/390,300, filed on August 7, 1989, the disclosure of which is incorporated by reference herein, as well as gp47-52 recognized by Group 1 mcAbs. The complex molecular organization of the HXLF gene family and the polymorphism of its related gCII glycoproteins suggest that HCMV has evolved these glycoproteins for some essential biological function.
These glycoproteins and glycoprotein complexes are important in maintaining the structural integrity of the virion, and also play an essential role in
biological processes essential to viral infectivity (i.e., adsorption, penetration), virion assembly, and cell-to-cell spread. Since currently available means of prevention and treatment of HCMV-related infections are of limited benefit, a goal of the present invention is the development of a pharmaceutical composition that can significantly reduce the incidence and severity of HCMV infections. A particular objective of the invention is the production of a pharmaceutical composition that is
active against HCMV in both the extracellular phase or early stage of HCMV infection and the intracellular phase or late stage of HCMV infection. Such a
composition would be useful for treating individuals with established HCMV infections as well as for
prophylaxis for those who are highly susceptible to HCMV infection. Yet another goal is the development of a composition which is active against virtually all strains of HCMV and will forestall the development of resistent strains of HCMV. A further goal is to develop a pharmaceutical composition active against HCMV which will reduce the risk of HAMA response in a patient.
Summary of the Invention
These and other goals are met by the present invention which is directed to an immunogenic cocktail composition and a method for its use in medical
treatment of HCMV infection. More specifically, the cocktail composition, which is suitable for both
diagnostic and therapeutic use, constitutes a mixture of at least two HCMV-specific immunoglobulins.
All immunoglobulins selected for the mixture bind with HCMV envelope glycoproteins and/or their complexes. Generally, the cocktail contains at least two anti-viral immunoglobulins each of which binds with a different segment of HCMV envelope glycoproteins or complexes. Preferably, these segments incorporate different, unique, non-competing epitopes on the same or different HCMV envelope glycoproteins. This function produces cocktail reactivity with multiple strains of HCMV. Preferably within the mixture, the
immunoglobulins, at least in part, exhibit synergistic anti-viral neutralizing activity against HCMV and are active against different phases of HCMV infection.
It is especially preferred that at least one of the immunoglobulins of the mixture will enhance the neutralizing activity of another member of the mixture
and those or other members will exhibit complement- dependent and complement-independent anti-viral
activity, and will be active against intracellular and extracellular HCMV glycoproteins.
A preferred embodiment of the mixture combines three immunoglobulins, two being the synergistic pair of which one provides complement-dependent anti-viral activity, and the third providing complement-independent anti-viral activity.
Another preferred embodiment of the mixture combines four immunoglobulins, two providing synergistic anti-viral activity against HCMV, a third exhibiting complement-dependent anti-viral activity, and a fourth providing complement-independent anti-viral activity.
Immunoglobulins which are suitable for the composition of the invention include HCMV-specific antibodies such as murine monoclonal antibodies (mcAbs), immunogenic fragments thereof such as Fab, F(ab)2 and their mixture with Fc, human monoclonal antibodies, chimeric antibodies carrying human constant regions, and altered human antibodies carrying hypervariable segments derived from HCMV-specific antibodies from a differing mammalian source. Murine mcAbs are among those
preferred.
A highly preferred embodiment of the
composition of the invention is the mixture of four murine mcAbs designated as MM-HCMV-9B7, MM-HCMV-41C2 , MM-HCMV-F15-3B10, and MM-HCMV-15F9 (In Vitro
International deposit nos. IVI-10117, IVI-10119, IVI- 10207, and IVI-10182, respectively). (MM refers to an internal code designation of the manufacturer,
Medimorphics).
When the cocktail composition is to be employed as a pharmaceutical composition for therapeutic and prophylactic treatment of HCMV infection in humans, it will be composed of a therapeutically effective amount of the foregoing immunoglobulin mixture with a
pharmaceutically-acceptable carrier. The carrier is preferably a liquid.
When the cocktail composition is to be employed for diagnostic purposes such as in vitro analysis, it will be composed of appropriate diagnostic amounts of the foregoing immunoglobulin mixture, optional suitable diluents whether or not pharmaceutically acceptable and optionally, detection markers or tags for measurement of the amount of HCMV detected.
The invention is further directed to a method of therapeutic and prophylactic medical treatment for HCMV infection which involves administering a
therapeutically effective amount of pharmaceutical composition to a patient.
The invention is also directed to a method of making the immunogenic cocktail composition which involves selecting compatible immunoglobulins which manifest certain predetermined activity against HCMV, and combining the immunoglobulins with a suitable carrier. In the case of a pharmaceutical composition, a pharmaceutically-acceptable carrier is combined with the mixture. Preferably, the carrier is a liquid.
Detailed Description of the Invention The cocktail composition of the present invention combines several HCMV-specific
immunoglobulins. This cocktail provides a preparation useful for the treatment of early and/or late HCMV infections in humans caused by virtually all strains of HCMV.
The immunoglobulins useful in the mixture may be derived from various sources, the preferred type being monoclonal antibodies. Tables 2-8 outline
examples of mcAbs for the mixture. Monoclonal
antibodies for a particular mixture may be derived from hybridomas or other cell lines (i.e., EBV-transformed lymphoblastoid cell lines, transfected mammalian cell
lines expressing immunoglobulin genes) that generate human, chimeric, bi-specific rearranged and murine antibodies. The unique specificity and functional activity of the murine HCMV-specific mcAbs in the cocktail have been precisely characterized and those structural features of the murine mcAbs that provide the specificity and activity can be engineered into chimeric human-mouse mcAbs exhibiting similar therapeutic
advantages. Alternatively, hybridomas producing human antibodies of similar specificity can be obtained by immunizing and/or screening with purified HCMV peptides recognized by the murine mcAbs in the cocktail. Methods to prepare these antibodies have been previously
described in U.S. Patent Nos. 4,816,397 and 4,816,567. In addition, F(ab) or F(ab')2 fragments may be utilized alone or in combination with Fc fragments. For methods to prepare these immunogenic fragments, see, for
example, Darnell et al., Molecular Cell Biology,
Scientific American, Inc., New York, NY (1986) at pages 77-78.
It is preferred that the immunoglobulin members of the cocktail react with as many naturally occurring strains of HCMV as possible while exhibiting no cross- reactivity with other viruses or normal cellular
proteins. It is further preferred that the cocktail contain at least two different anti-viral
immunoglobulins that are reactive with unique, non- competing epitopes on the same or different HCMV
envelope glycoproteins. In addition to the foregoing benefits, this structure and activity relationship will immunoreact with existing strains of HCMV and prevent the emergence of future strains of HCMV which would be otherwise resistent to the anti-viral activity of an immunoglobulin mixture.
Several factors are taken into consideration in selecting a particular immunoglobulin for the mixture. The cocktail comprises an immunoglobulin mixture that
exhibits specificity for multiple epitopes, augmenting activity, and synergistic anti-viral activity directed against mechanisms associated with both extracellular viral infection and established intracellular
replicating viral infection. A single immunoglobulin may function in more than one capacity. A particular immunoglobulin is thus selected on the basis of its reactivity with specific epitopal sites on an HCMV glycoprotein complex or component glycoprotein, its synergistic activity in combination with other
immunoglobulins, its complement-dependent or complement- independent anti-viral activity against HCMV, and its activity against early stage extracellular HCMV or late stage intracellular HCMV.
Immunoglobulins used in the cocktail are reactive with HCMV envelope glycoproteins. Since those glycoproteins are expressed on the surface of HCMV virions as well as on the membranes and in the cytoplasm of cells which have become infected with the virus, the preparation provides neutralizing activity against both extracellular and intracellular HCMV virions.
The selection of a particular immunoglobulin depends on the type of anti-viral activity sought. In particular, the cocktail contains at least two HCMV- specific immunoglobulins that exhibit anti-viral
activity by different neutralizing actions wherein the activity is effective against different stages of HCMV infection. It is preferred that the cocktail combine at least two monoclonal antibodies with different anti- viral activity selected from the following types of neutralizing actions:
Neutralizing Action Characteristics of mcAbs
(i) Lysis of extracellular Complement-fixing mcAbs
infectious virus reactive with neutralizing epitopes on HCMV envelope glycoproteins and complexes
(ii) Inhibition of virus Blocking mcAbs which react adsorption or with HCMV envelope
penetration into glycoproteins and complexes host cells essential for adsorption and/or fusion with cell membranes
(iii) Inhibition of virion Inhibitory mcAbs
assembly, cell-to-cell reactive with essential spread structural HCMV
envelope glycoproteins
(iv) Lysis of HCMV-infected
host cells
(a) antibody-mediated Complement-dependent or
cytolysis -independent cytolytic
mcAbs reactive with HCMV glycoproteins and
complexes on the surface of infected cells which directly lyse the virus- infected cell
(b) cell-mediated Complement-dependent or
cytoxicity -independent mcAbs
which mediate
lymphocyte killing
of infected cells (i.e., antibody-dependent cellular cytoxicity (ADCC) )
More particularly, immunoglobulins are combined which react with different glycoprotein complexes (gC) and with different glycoproteins (gp) within those complexes. The most abundant HCMV envelope
glycoproteins and glycoprotein complexes are summarized in Table 1.
Various neutralizing immunoglobulins specific to the gCI glycoprotein complexes inactivate
extracellular HCMV, block viral adsorption to target organs, and/or prevent penetration of HCMV into tissues. The gCI-specific immunoglobulins include those which are reactive with glycoproteins with molecular weights of 130,000 (gpl30), 93,000 (gp93) and 55,000 (gp55). Among the gCI-specific mcAbs preferred are those outlined in Table 2 and Table 3, as shown below.
According to one embodiment of the invention, the gCI- specific immunoglobulins include MM-HCMV-9B7, a gp55- specific neutralizing IgG2b mcAb (deposit no. IVI-10117), MM-HCMV-41C2, a gp55-specific non-neutralizing IgGi mcAb (deposit no. IVI-10119), and MM-HCMV-F15-3B10, a gp93- specific neutralizing IgGi mcAb (deposit no. IVI-10207). (MM refers to an internal code designation of the manufacturer, Medimorphics).
The further inclusion of an immunoglobulin specific to the gCII complex may inhibit HCMV adsorption and penetration of tissues, intracellular virion
assembly, and/or cell-to-cell spread. Immunoglobulins specific to the gCII complex include Group 1 gCII immunoglobulins which are reactive with gp47-52 and recognize membrane-associated glycoproteins, and Group 2 gCII immunoglobulins which are recognize gp38-47, gp90 and gp200 of gCII and exhibit activity against
intracellular proteins. Among the gCII-specific mcAbs preferred are those listed in Table 4, as shown below.
According to one embodiment of the invention. Group 1 gCII-specific immunoglobulins include MM-HCMV-9E10, a gp47-52-specific neutralizing mcAb (deposit no. IVI- 10118), and MM-HCMV-8B4, MM-HCMV-8B2, and MM-HCMV-26E11, three gp47-52-specific non-neutralizing mcAbs. Group 2 gCII-specific immunoglobulins include, among others, MM- HCMV-15F9, a non-neutralizing mcAb specific to gp38-47, gp90 and gp200 (deposit no. IVI-10182).
According to the invention, it is preferred that immunoglobulins specific to gp55 and gp93 of the gCI glycoprotein complexes are combined with
immunoglobulins which react with gp38-47, gp90 and gp200 of the gCII complexes containing Group 2 glycoproteins. The antigen specificity and the anti-viral activity of such preferred mcAbs selected for the mixture of an
HCMV-specific mcAb cocktail, as summarized in Table 5 below.
At least one immunoglobulin specific to the gCI glycoprotein complex of HCMV may be selected for its complement-dependent neutralizing activity. The
complement-dependent neutralization of HCMV may involve extracellular lysis of virions. Preferably this
neutralizing activity is directed against a complement- dependent epitope of gp55 of the gCI glycoprotein complexes. Among the embodiments of those mcAbs
preferred for this activity are MM-HCMV-39E11, MM-HCMV- 18F9, and MM-HCMV-9B7, as characterized in Table 2.
According to an embodiment of the invention, MM-HCMV- 9B7, a murine IgG2b mcAb (deposit no. IVI-10117), can be selected for the mixture for its complement-dependent neutralizing activity with an epitope on gp55.
At least one immunoglobulin which exhibits complement-independent neutralizing activity toward the gCI glycoprotein complexes of HCMV may also be selected for the mixture. This activity may interfere with HCMV infectivity by blocking adsorption to viral receptors expressed on target organs and by preventing the
penetration of HCMV into susceptible cells. Among those mcAbs preferred for this activity are MM-HCMV-3C2, MM- HCMV-9F9, and MM-HCMV-F15-3B10, all of which are
specific to complement-independent epitopes on gp93 of the gCI glycoprotein complexes, as characterized in
Table 3. For this particular member of the mixture, an embodiment of the invention can include MM-HCMV-F15- 3B10, a murine IgG1 mcAb.
At least one immunoglobulin may be incorporated into the mixture based on its reactivity against Group 2 glycoproteins in gcll glycoprotein complexes of HCMV. Reactivity against gCII glycoprotein complexes may interfere with late stage intracellular HCMV by
preventing virion assembly and/or cell-to-cell spread of the virus. Table 4 outlines Group 2 gCII mcAbs which are among those preferred for this activity. An
embodiment of this kind of mcAb is MM-HCMV-15F9, a
murine IgG2a mcAb (deposit no. IVI-10182) which is reactive with gp38-47, gp90 and gp200 of the gCII glycoprotein complexes containing Group 2 glycoproteins.
At least one immunoglobulin is selected to inactivate extracellular HCMV associated with the early stage of infection and at least one immunoglobulin is selected to inhibit intracellular HCMV once infection of tissues has occurred. The combination of
immunoglobulins which neutralize or inhibit HCMV in different stages of infectivity increases the
effectiveness of a preparation directed at inhibiting HCMV infection over a wide range of situations.
According to the invention, early stage antiviral activity against HCMV is provided by gCI- specific immunoglobulins with complement-dependent and complement-independent neutralizing activity while late stage inhibitory activity against intracellular HCMV is provided by Group 2 gCII-specific immunoglobulins. In a preferred embodiment of the invention, MM-HCMV-9B7, a murine IgG2b mcAb specific to gp55 of the gCI
glycoprotein complex of HCMV, can provide complement- dependent neutralization which involves extracellular lysis of HCMV virions. MM-HCMV-F15-3B10, a complement- independent murine IgGj mcAb specific to gp93 of the gCI complex, may also interfere with early stage exogenous
HCMV by inhibiting viral adsorption and penetration into susceptible cells. The Group 2 gCII-specific murine IgG2a mcAb MM-HCMV-15F9 may inhibit intracellular virion assembly and/or cell-to-cell spread of HCMV.
At least two immunoglobulins are selected because of their synergistic enhancement of neutralizing activity against HCMV that occurs when the
immunoglobulins are combined. It is preferred that the immunoglobulins are reactive with unique, augmenting epitopes on the same or different HCMV envelope
glycoproteins such that the anti-viral activity of the immunoglobulins in combination is substantially greater
than the sum of the activities of each immunoglobulin acting alone. The augmenting activity may result from the molecular interactions between immunoglobulins reactive with epitopes in close spatial proximity on the conformational structure of a single glycoprotein or from interactions between immunoglobulins directed against different glycoproteins. It is preferred that at least one immunoglobulin react with a non- neutralizing epitope to cause conformational changes in the three-dimensional structure of the glycoprotein which in turn increases the accessibility of the second immunoglobulin toward a neutralizing epitope.
Preferably the neutralizing activity is directed at a complement-dependent epitope of the gCI glycoprotein complexes. The result of the combined activity of the immunoglobulins is an increase in the complement- dependent activity of the neutralizing immunoglobulin.
This synergistic activity may be provided by combining mcAbs specific to Domain I of the gCI
glycoprotein complexes with mcAbs specific to Domain II of the gCI glycoprotein complexes. Among those Domain I and II mcAbs that are preferred are those outlined in Table 2. According to the invention, an embodiment providing this activity may be two mcAbs specific to gp55 on the gCI glycoprotein complexes of HCMV. These mcAbs are selected for their synergistic
immunoreactivity and neutralizing activity when
combined. In particular, MM-HCMV-41C2 , a murine IgG1 mcAb (deposit no. IVI-10119), can be selected for its non-neutralizing activity with an epitope located in close spatial proximity on the conformational structure to the epitope recognized by MM-HCMV-9B7 in order to augment the complement-dependent neutralizing activity of MM-HCMV-9B7 and enhance extracellular lysis of HCMV virions.
Representative sources of monoclonal antibodies reactive with HCMV envelope glycoprotains are provided in Tables 6 and 7 shown below.
Hybridomas producing HCMV-specific mcAbs that are deposited at ln Vitro International, Inc. are listed in Table 8 shown below.
Different formulations of the cocktail can be achieved by mixing the mcAbs in different proportions and combining the mixture with the carrier. It is preferred that a range of ratios and immunoglobulin concentrations of various combinations of
immunoglobulins be evaluated according to
microneutralization assay and the proportion of a mcAb member within the mixture be selected from the
corresponding range of augmenting anti-viral activity. For a mixture of two mcAbs, it is preferred that ranges of 100:1 to 1:100 be evaluated. According to the invention, a 10-100 fold increase in the neutralizing activity has been observed in 9B7:41C2 over a range of 1:10 to 1:500, in 41C2:34G7 over a range of 1:20 to 1:200, and in 34G7:41C2 over a range of 1:10 to 1:1000. In a four mcAb mixture, it is preferred that the three mcAbs that exhibit unique specificity and anti-viral activity directed at different HCMV glycoproteins be combined in equimolar ratios within a range of 100:1 to 1:100 for all components. In particular, it is
preferred that the ratio of the embodiment MM-HCMV-9B7: MM-HCMV-F15-3B10: MM-HCMV-15F9 is 1:1:1. It is further preferred that the pair of augmenting gCI-specific mcAbs, in particular MM-HCMV-9B7:MM-HCMV-41C2, are combined in a ratio within a range of 100:1 to 1:100 depending on the optimal ratio that will achieve maximum synergistic anti-viral activity of the two mcAbs alone and in combination with other mcAbs in the cocktail.
The invention also provides for use of the cocktail composition for in vitro detection of HCMV infection. The synergistic binding activity of a combination of immunoglobulins in the cocktail
composition can be used to increase the sensitivity of detection of extracellular HCMV virions in clinical specimens (i.e., urine, saliva, bronchoalveolar lavage fluid) and HCMV transplant organs, blood products, or biopsy/autopsy specimens over any single immunoglobulin.
The combination of a primary immunoglobulin labeled with a suitable detection molecule together with one or more augmenting immunoglobulins which increase the binding of the primary antibody to its target antigen can be used in any immunoassay format, including radioimmunoassay (RIA), enzyme-linked immunosorbant assay (ELISA), or immunofluorescence (IF) to increase the sensitivity of detecting HCMV virions and glycoproteins.
The invention also provides for a
pharmaceutical composition comprising an amount of the immunoglobulin mixture which is effective to inhibit HCMV infectivity in a patient, when administered
thereto, in combination with a pharmaceutically- acceptable vehicle such as a liquid carrier. The pharmaceutical composition is useful for treating patients with established HCMV infection and for
preventing HCMV infection through prophylactic
administration of the composition to high-risk
individuals .
The carrier of the pharmaceutical composition may be any material which is otherwise inert, medically- acceptable and compatible with the active ingredients of the composition, and which assists in administering the immunoglobulin mixture to the patient. The carrier may be comprised of a physiologically balanced salt
solution, with or without additional protein such as albumin, in order to reach a composition similar to that of human plasma suitable for parenteral intravenous or intramuscular administration. The carrier may
incorporate buffers, extenders, solubilizing agents, stabilizing agents, and the like.
The pharmaceutical composition can be formulated as a powder, granules, solution, dispersion, aerosol, powder, or drops. The solution may be sterile, isotonic, and suitable for parenteral administration by intravenous, intramuscular, intraperitoneal, or
subcutaneous injection. In addition to an effective
amount of the composition, the solution may contain appropriate adjuvants, buffers, preservatives and salts. The solution is preferably aqueous. The powder or granular forms may be combined with a solution and with diluting, dispersing and/or surface active agents.
Solutions such as nose drops may contain antoxidants, buffers and the like.
The invention further provides for methods of medical treatment of HCMV infection utilizing the pharmaceutical preparation of the immunoglobulin
cocktail. One method of treatment involves
administering an effective amount of the pharmaceutical preparation as a prophylactic therapy for patients who are highly susceptible to HCMV infection. In
particular, the cocktail composition may be administered to organ and bone marrow transplant recipients, HIV- seropositive patients, pregnant women exposed to or infected with HCMV in order to prevent symptomatic congenital HCMV infection of the developing fetus, and other high-risk individuals. Another method of
treatment entails therapeutic intravenous,
intraperitoneal, subcutaneous or intramuscular
administration of the pharmaceutical composition to patients with established HCMV infections including HCMV-seropositive patients and those with acquired immune deficiency (AIDS) and HCMV infections.
In vitro neutralization data indicate that the serum concentration of total murine immunoglobulin in patients should be maintained at greater than or equal to 1 ug/ml. Although it is ultimately the physician's decision as to the amount of the pharmaceutical
composition to be administered to a patient, the
composition may typically be administered in a single dose or in multiple doses at effective non-toxic dose levels of about 1 mg/kg/day of the cocktail per body weight, based on a half-life of at least eight hours and non-synergistic anti-viral activity by the cocktail. ln
vitro comparisons show the activity of the cocktail combination of mcAbs at a level of more than 100 times that of HCMV hyperimmune globulin. This increased activity derives from combining only HCMV-specific mcAbs in the preparation and from including in the mixture immunoglobulins which synergistically immunoreact to augment the activity of a neutralizing mcAb. Where synergistic activity is demonstrated in vivo, either the quantity of mcAb cocktail administered per dose may be reduced or the interval between doses may be increased.
The pharmaceutical composition may be administered rectally, vaginally, ocularly, nasally, intravenously, intramuscularly, intraperitoneally, or subcutaneously.
A composition composed of a mixture of HCMV- specific monoclonal immunoglobulins has several
advantages over the existing single HCMV-specific monoclonal antibody preparations or human HCMV
hyperimmune globulin medications. Those treatments have met with limited success due to the nature of HCMV and its different phases of infection, that is its early extracellular phase and its late stage intracellular phase. Moreover, the occurrence of multiple strains and mutated forms of HCMV limits the therapeutic effect of administering preparations comprised of a single
immunoglobulin.
One advantage of the cocktail composition is that activity against HCMV is extended from a single phase of HCMV infection to several phases. HCMV has a slow replication cycle compared to that of other herpes viruses and is highly cell-associated, making HCMV relatively inaccessible to humoral antibodies.
Moreover, HCMV uses certain host cell enzymes for its replication rather than virus-specific enzymes which are involved in the activity of some antiviral drugs. The invention combines together multiple immunoglobulins which are directed at different phases of HCMV
infection, namely the extracellular phase which is associated with the early stages of infection and the intracellular phase which occurs in the late stages of actual infection of tissues . This feature of the anti- HCMV immunoglobulin cocktail makes the preparation useful for treating individuals with established HCMV infections by inhibiting spread of HCMV in the
bloodstream and the progression of HCMV in infected organs, and also for preventing HCMV infections in high risk individuals such as transplant patients and those with AIDS.
This broad therapy against established HCMV infections, which is provided by incorporating both gCI- specific and gCII-specific immunoglobulins into the mixture, is a distinct improvement over existing
treatments. Sera from patients recovering from HCMV infection have been shown to contain antibodies reactive with gp55, gp93 and gpl30 of the gCI complex of HCMV, and with Group 1 and Group 2 glycoproteins in gCII complexes. In contrast, sera obtained from infants with symptomatic congenital HCMV infection and their mothers showed reactivity with gpl30, gp55 and gp93 of the gCI glycoprotein complex but not with either Group 1 or Group 2 gCII glycoproteins. The presence of gCI- specific antibodies in the sera of both groups of patients suggests that antibodies specific to the gCI glycoprotein complex may not be sufficient for recovery from persistent HCMV infection. Furthermore, the lack of gCII antibodies in congenital HCMV infants with persistent viruria suggests an important role for these antibodies. Therefore, the present invention provides an improvement over existing preparations directed at established HCMV infections because it combines both gCI-specific and gCII-specific immunoglobulins into the cocktail composition.
The multi-immunoglobulin cocktail of the present invention also provides activity against
multiple strains of HCMV and decreases the incidence of resistant strains of HCMV which are likely to emerge during prolonged administration of a single HCMV
immunoglobulin. It has been found that immunosuppressed patients are frequently infected with multiple rather than single strains of HCMV. Although most HCMV- specific mcAbs recognize cross-reactive antigenic determinants, HCMV envelope glycoprotein epitopes have been identified which are uniquely expressed by
particular strains of HCMV or which have been deleted altogether in other strains. The mcAb cocktail provides activity not only against multiple strains of HCMV but virtually all naturally occurring strains of HCMV. As such the cocktail provides an improvement over existing preparations because it will be useful in treating all immunosuppressed patients, irrespective of how many strains of HCMV are present. In addition, in vitro propagation of HCMV in the presence of particular mcAbs has resulted in mcAb-resistant (mar)-mutant viruses which have selectively deleted the epitope recognized by that particular antibody. Assuming that such HCMV mutant viruses occur with a frequency of approximately 10-6, the probability of mutant strains developing in patients receiving immunoprophylaxis with an mcAb cocktail embodiment wherein four separate epitopes are deleted is approximately 10-24. Therefore, the cocktail composition of the invention is a distinct advantage over single mcAb formulations by virtue of the mixture which, because of its reactivity with unique epitopes of the HCMV envelope glycoprotein, virtually eliminates the possibility of HCMV viral resistance.
A further advantage of the composition of the invention is its increased level of activity against HCMV as compared to existing therapies. High-risk patients such as organ and bone marrow transplant recipients, patients with congenital or acquired immune deficiency diseases, and patients receiving
immunosuppressive drugs frequently develop life- threatening opportunistic HCMV infections which are unresponsive to currently available anti-viral drugs and HCMV-hyperimmune globulin. In vitro assays show a level of activity in the cocktail composition of 100 times that of HCMV hyperimmune globulin. As a result of this enhanced activity, the quantity of monoclonal antibody protein required to achieve a desired anti-viral effect is reduced, thereby decreasing the amount and/or
frequency of antibody to be administered. This has the advantage of simplifying a dosage regime, minimizing the risks of allergic reactions, and reducing production costs.
The increased level of activity of the composition of the invention stems in part from its make-up. Unlike existing globulin preparations which, besides various other components, include antibodies directed at substances other than HCMV, the cocktail composition is comprised exclusively of HCMV-specific mcAbs. As such, the cocktail preparation is a distinct advantage over existing preparations because it is able to provide HCMV-specific antibodies in plasma and interstitial fluid at a level sufficient to inactivate HCMV as an exogenous virion and as an intracellular replicating virion.
The heightened activity of the cocktail is also a result of the synergism that occurs between certain members of the immunoglobulin mixture whereby the binding and neutralizing activity of at least one of the members is augmented. As a result of the enhanced activity, the total amount of immunoglobulin (Ig) protein which must be administered to attain a
particular inhibiting effect against HCMV is reduced. This is particularly desirable in order to decrease the risk of human anti-mouse antibody (HAMA) response which occurs in the majority of patients receiving therapeutic murine antibodies and to a lesser extent in patients
receiving chimeric mouse-human monoclonal antibodies, human-human monoclonal antibodies, and F(ab')2 fragments of murine and human monoclonal antibodies. It has been shown that HAMA responses reduce the half-life of murine mcAbs by altering the pharmokinetics and biodistribution of the therapeutic mcAb. It has been further shown that the incidence and extent of the HAMA response increases in patients receiving large amounts of murine Ig protein in multiple doses over an extended period of time.
Since it is preferable, therefore, to limit the total amount of immunoglobulin protein which is administered, the composition of the present invention provides an advantage over existing preparations.
The anti-isotypic HAMA response to the mcAb cocktail combination is likely to be comparable to that of an equivalent amount of a single mcAb. In contrast, the human antibody response to four different idiotypic determinants on the hypervariable regions of F(ab) regions of the four mcAbs in the cocktail may be reduced as compared to the response to a larger quantity of a single HCMV-specific mcAb that expresses a single idiotope. Since anti-idiotypic antibodies are more likely to interfere with the biologically active sites on the therapeutic mcAb, a reduction in that HAMA response represents a significant advantage to the mcAb cocktail composition.
The cocktail of the present invention is especially effective in diagnosing and detecting the presence of HCMV in patients, transplant material, and blood products. By combining into one preparation, mcAbs that are active against different glycoproteins expressed by virtually all strains of HCMV, in vitro detection of HCMV virions is greatly enhanced over single HCMV-specific mcAb preparations. The increased sensitivity of the cocktail ensures that its use in a diagnostic test will provide detection of all strains of HCMV. Moreover, both extracellular virions in clinical
samples and HCMV glycoproteins expressed on the surface of infected tissues will be detected by the cocktail composition. EXAMPLE 1
Methods for production and characterization of the HCMV-specific monoclonal antibodies in the cocktail.
Generation of monoclonal antibodies to gp55 of gCI Monoclonal antibodies were generated by using purified Towne HCMV virions as the immunizing antigen. Adult BALB/c mice were immunized intraperitoneally with antigen emulsified in complete Freund's adjuvant, followed with three booster immunizations using saline- suspended immunogen given at three-week intervals.
Three days following the final booster, the mouse was sacrificed and the spleen cells fused with SP2/0 - Ag14 myeloma cells (American Tissue Culture Collection) at a ratio of 4:1 using polyethylene glycol. Twenty-four hours later, the fused cells were distributed into 96 wells in Hepes-buffered Dulbecco's modified Eagle's medium (DMEM) supplemented with 10% fetal bovine serum, 50 ug/ml garamycin, 13.6 ug/ml hypoxanthine, 0.4 rø aminopterin and 7.6 ug/ml thymidine. After two weeks in this medium, the cells were transferred to new medium supplemented as above but without aminopterin. Three to four weeks after cell fusion, supernatants from these cultures were assayed for antibodies specific to HCMV NP-40 extract by an ELISA assay. Cloning of cells from positive cultures was performed by limiting dilution using mouse thymocytes as feeder cells. Individual wells were screened microscopically for single colonies and assayed for antibody to HCMV NP-40 extract as above. Antibody-producing clones were expanded for production of ascites fluid in BALB/c mice.
Generation of monoclonal antibodies to gρ93 of gCI McAbs which recognize gp93 were made by using purified gp93 from Towne strain HCMV as the immunizing agent in BALB/c mice. The virus was grown on skin fibroblasts according to Kari, et al., J. Virology
60:345-352 (1986). Extracellular virus was partially purified from culture media by differential
centrifugation. To purify gp93 for the purpose of making mcAbs, gCI complex was immunoaffinity purified from a non-ionic detergent extract of HCMV using a gp55- specific biotinylated mcAb and streptavidin-agarose according to Gretch et al., Anal. Biochem. 163:270-277 (1987). The gCI complex was reduced and separated by SDS-PAGE in a 9% polyacrylamide gel using the method of Laemmli, Nature 227:680-684 (1970). Proteins were detected by Commassie blue staining and the gp93 band was cut from the polyacrylamide gel. The glycoprotein was electroeluted from the gel slice and SDS was removed from the protein with a 0.5 ml column of Extracti-gel D (Pierce Chemical Co.). Mice were immunized with
purified gp93 to make mcAbs. Production and
characterization of mcAbs were done according to Kari et al. (1986). Two mcAbs were obtained: 3C2 (IgG1) and 9F9 (IgG1). MM-HCMV-F15-3B10 was derived by further
subcloning of 3C2.
Generation of gCII monoclonal antibodies Adult BALB/c mice were immunized with 100 ug of whole Towne strain HCMV emulsified in complete Freund adjuvant and given a booster immunization with 100 ug whole Towne HCMV at three weeks. After several weeks a final boost was given using 20 ug of gCII which was purified by anion exchange high performance liquid chromatography according to Kari et al., (1986). Three days following the final boost with gCII, the mice were sacrificed and the spleen cells were fused with Sp2-0- Agl4 myeloma cells. Cloning was done according to Kari
et al. (1986). To identify positive hybridomas, culture medium was assayed for antibody against gCII by enzyme linked immunosorbant assay. For this assay, purified gCII was fixed in 96 well dishes. Hybridomas were subcloned twice by limited dilution. All mcAbs used in these studies were subtyped and found to have a single subtype. Clonality was further assayed by agarose isoelectric focusing of purified mcAbs. Purification of monoclonal antibodies
Monoclonal antibody from ascites was purified by high-performance hydroxylapatite chromatography, according to Juarez-Salinas et al., Biotechniques
(May/June 1984).
EXAMPLE 2
Radioactive labeling of HCMV proteins and
immunoprecipitations
Glycoproteins were radiolabeled with [14C]GlcN or [3H]Arg (New England Nuclear) according to Kari et al. (1986). Labeled proteins were extracted from either extracellular virus or from infected whole cells using a Tris buffer (50mM Tris, pH 7.5, 150 mM NaCl, ImM
phenylmethylsulfonyl fluoride (PMSF)) containing 1.0% NP-40. Insoluble material was removed from
centrifugation. Monoclonal antibodies, biotinylated according to Gretch et al. (1987), were added to these extracts along with streptavidin agarose beads (BRL). These solutions were mixed for one hour at room
temperature and centrifuged to pellet the agarose beads. After several washes with PBS containing 0.1% NP-40, bound proteins were solubilized with SDS-PAGE sample solubilization buffer by heating at 100° C for three minutes. After SDS-PAGE, radioactive proteins were detected by fluorography using 3H Enhance (New England Nuclear).
SDS-PAGE and Western blot
SDS-PAGE was done with either 7% or 10% polyacrylamide gels following the method of Laemmli (1970). Proteins in these gels were electroblotted onto nitrocellulose paper and the paper was then blocked with 3% gelatin in Tris-phosphate buffered saline (TBS, 20 mM Tris, 500 mM NaCl, phenylmethylsulfonyl fluoride (PMSF) 2 mM, pH 7.5). Strips of the blocked paper were
incubated overnight with mcAbs in ascites diluted 1 to 500 in TBS containing 1% gelatin. Strips were washed with TBS containing 0.05% Tween 20 and then with TBS before incubation with phosphatase labeled goat anti- mouse IgG or goat anti-human IgG (Kirkegaard and Perry, Gaithersburg, MD) diluted 1 to 1000 with TBS containing 1% gelatin. After one hour incubation the paper was washed and the substrate 5-bromo-4-chloro-3-indoyl phosphate in 0.1 M Tris buffer (Kirkegaard and Perry) was added. After visualization the reaction was stopped by immersing the strips in water.
Immunofluorescence
Reactivity of the mcAbs with wild type and laboratory adapted strains (Towne, AD169, Toledo) of HCMV and several unrelated viruses was determined in an indirect immunofluorescence assay. Adenovirus, HSV, VZV, and wild type strains of HCMV were obtained from clinical isolates. For immunofluorescence, virus- infected and uninfected skin fibroblast cultures on glass slides were fixed in cold acetone:methanol (v/v, 1:1). Fixed cultures were preincubated with normal porcine serum and washed with phosphate-buffered saline (PBS). All subsequent steps were done with PBS
containing 0.1% NP-40. Cultures were incubated with HPLC-purified ascites mcAb or with tissue culture fluid for 30 minutes and washed with PBS NP-40 buffer.
Cultures were then incubated with fluorescein
isothiocyanate (FITC) labeled goat antimouse IgG
(Cappel, Malvern, Pennsylvania). Following a final wash, slides were examined with a Zeiss phase
fluorescence microscope.
Cells infected with Towne strain HCMV were then examined as either living or fixed cells. For these experiments, cells in 6 well culture dishes were
infected with Towne strain HCMV at a MOI of 3 x 10-4 or 3. With the low MOI, cultures were harvested at 12 days post infection, and at 4 and 7 days when an MOI of 3 was used. Living cultures were then stained by indirect immunofluorescence using HCMV-specific mcAbs to detect HCMV glycoproteins in the plasma membrane. Duplicate cultures which had been fixed with acetone: methanol were stained at the same time to detect internal HCMV glycoproteins. For staining, cells were incubated with HCMV-specific mcAbs in phosphate buffered saline (PBS) pH 7.5 at 37°C for 1 hour. Cultures were washed and incubated with fluorescein isothiocyanate-labeled goat anti-mouse immunoglobulin (Cooper Biomedical Inc., West Chester, Pa.). Following a final wash, cultures were examined with a Zeiss phase fluorescence microscope.
Neutralization assays
Monoclonal antibodies purified by
hydroxylapatite HPLC were diluted in DMEM supplemented with 2% fetal bovine serum (FBS). Prior to infection, 600 plaque-forming units (pfu) of Towne and 300 pfu of Toledo strain HCMV were added to mcAb in a total volume of 0.4 ml of DMEM. Guinea pig complement (Pel-Freeze Biologicals, Rogers, Arkansas) was added to a final concentration of 2.0% in half the preparations; the remaining half received an equivalent volume of DMEM. Viral neutralization was allowed to proceed for 60 minutes at 37°C. The HCMV-mcAb mixture was added to confluent layers of skin fibroblasts in 6-well plates (Costar, Cambridge, Massachusetts) and incubated for another 60 minutes for the virus to adsorb. The virus
mixture was aspirated and 5 ml of DMEM supplemented with
2% FCS, garamycin, penicillin G, and 0.5% agarose (Sea
Plaque, FMC Co., Rockland, Maryland) was added to each well. On day 8, the monolayers were fixed with 10% formalin in 70% ethanol, stained with methylene blue and the plaque counted. Viral neutralization was evaluated using the formula:
% Plaque Reduction =
Simultaneous two antibody binding assay Antigens were coated onto Immunolon 96-well microtiter plates. For this assay the antigens used were purified Towne strain whole virion and HCMV Towne strain glycoprotein complexes extracted from infected cell membranes with 1.0% NP-40. Extracted glycoprotein complexes were used either intact or reduced and
alkylated according to Kari et al. (1986). As a
control, uninfected fibroblasts were extracted with NP- 40 and proteins in these extracts were used to coat wells. To prevent interference from NP-40 on the ability of proteins to coat the wells, protein extracts were passed over a column of Extracti Gel-D (Pierce Chemical Co.) to remove NP-40. Wells were coated with the same amount of protein for each of the preparations used. Monoclonal antibodies used in this assay were purified by HPLC according to Kari et al. (1986) and biotinylated using biotin N-hydroxysuccinimide ester according to Gretch et al. (1987). A fixed amount of biotinylated antibody and varying amounts of a second unlabeled antibody were added simultaneously to each well and incubated for 90 minutes at room temperature.
Wells were washed three times with PBST and peroxidase
labeled streptavidin (Kirkegaard and Perry) diluted
1/2000 in PBST was added and incubated for 90 minutes.
After washing with PBST, the substrate OPD was added and
OD490 was read. The biotinylated antibody was titered beforehand to determine the amount of antibody needed to give an OD490 of 0.5 to 1.0 in the absence of a second unlabeled antibody. This assay was performed in
duplicate and the data were reduced using the following formula:
percentage augmentation or inhibition
=[(OD490 with 2nd mcAb)-(OD490 without 2nd mcAb)/(OD490 without 2nd mcAb)] x 100. EXAMPLE 3
Monoclonal antibodies reactive with HCMV
glycoproteins comprising the gCI and gCII complexes Complement-dependent and -independent neutralizing HCMV-specific mcAbs that are reactive with gpl30 and gp55 have been obtained, and mcAbs reactive with unique epitopes on gpl30 and gp93 have been
developed which exhibit complement-independent
neutralizing activity. A simultaneous competitive ELISA assay has been used to identify eight gCI-specific mcAbs reactive with unique continuous or conformation- dependent epitopes in three domains comprising a major B-cell antigenic region of gp55 in gCI complexes, which is the subject of U.S. Patent Application Serial No.
07/083,502, filed on August 7, 1987, the disclosure of which is incorporated by reference herein. Individual mcAbs in Domains I and II either augment or inhibit the binding of other gp55-specific mcAbs, and exhibit similar effects on virus neutralization in a plaque reduction assay. Monoclonal antibodies that are
reactive with conformation-dependent epitope(s) in
Domain III inhibit binding and neutralizing activity of all other gp55-specific mcAbs.
All of the gp55-specific mcAbs
immunoprecipitate gCI complexes and react with gp130, gp55 and proteolytic cleavage fragments obtained from digestion with chymotrypsin in Western blot analysis but do not react with gp93. In contrast, gp93-specific mcAbs react with gp130 and gp93 but do not react with gp55. Both gp55-specific and gp93-specific mcAbs immunoprecipitate unreduced gCI complexes which
indicates that the gCI complex contains both of those glycoproteins.
At least one gCII-specific mcAb has been described which variably exhibits complement-independent neutralizing activity against Towne strain HCMV and which has been shown to recognize an epitope uniquely expressed on gp47-52 of gCII complexes, as claimed in U.S. Patent Application Serial No. 06/933,789, filed on November 24, 1986, the disclosure of which is
incorporated by reference herein. Two non-neutralizing mcAbs reactive with gp47-52 have been identified and designated as Group 1 gCII mcAbs, as claimed in U.S. Patent Application Serial No. 07/390,300, filed on
August 7, 1989, the disclosure of which is incorporated by reference herein. A second group of gCII-specific mcAbs has been developed which reacts with gp38-47, gp90 and gp200 in the higher molecular weight gCII complexes, but which is non-reactive with gp47-52, as claimed in U.S. Patent Application Serial No. 07/390,300, filed on August 7, 1989, the disclosure of which is incorporated by reference herein. Of interest. Group 1 gCII mcAbs recognize membrane-associated glycoproteins, whereas Group 2 mcAbs recognize intracellular proteins.
Antibodies that are directed against gCII glycoproteins are likely to inhibit virion adsorption and penetration, virion assembly, and/or cell-to-cell spread.
EXAMPLE 4
The human antibody response to HCMV glycoproteins comprising the gCI and gCII complexes
Sera from patients who recover from HCMV infection contain antibodies reactive with structural virion proteins and glycoproteins and which exhibit neutralizing activity in the presence or absence of complement in vitro. Convalescent sera were examined by immunoprecipitation or Western blot analysis using HCMV- infected cell lysates or whole virions as antigens.
Among the proteins recognized were gp55 and gpl30 of the gCI complex. Of interest, no human antibodies reactive with gp93 of gCI or any of the Group 1 or Group 2 gCII glycoproteins were detected using whole viral antigen preparations.
Purification of individual gCI and gCII glycoproteins prior to immunological analysis has confirmed the importance of those glycoproteins in the human antibody response in normal individuals. It has also lead to the detection of a deficient level of gCII- specific antibodies in infants with symptomatic
congenital HCMV infection and in their mothers. Human HCMV-positive convalescent sera recognize B-cell
epitope(s) on unreduced gCI complexes and proteolytic fragments, and also react with gpl30, gp55, and gp93 in Western blot analysis. In addition, human sera
immunoprecipitate unreduced gCII complexes, and most react with individual Group 1 and Group 2 gCII
glycoproteins in Western blot analysis. However, one of eight HCMV-positive adult donors tested lacked
antibodies reactive with Group 1 or Group 2 gCII glycoproteins.
Longitudinal serum specimens taken from infants, ranging in age from 1 to 63 months, with symptomatic congenital HCMV infection and persistent viruria, were examined for the presence of human
antibodies to gCI and gCII glycoproteins. All infant sera contained antibodies reactive with gp130, gp55, and
gp93, but none contained antibodies reactive with Group 1 or Group 2 gCII glycoproteins. Infant sera obtained during the first six to nine months following birth were non-reactive with gCII glycoproteins, which indicates a possible deficit in the mother's antibody response to the gCII glycoproteins. In addition, sera taken 32 and 63 months postpartum from two mothers of infants with congenital HCMV infections did not contain gCII-specific antibodies but did have antibodies that were reactive with gCI glycoproteins. In contrast, gCII-specific antibodies were detected in sera taken from fraternal twins, one with asymptomatic congenital infection and the other with an HCMV infection acquired at six months of age. These data indicate that susceptibility to the pathogenic effects of HCMV may be associated with maternal/fetal non-responsiveness to gCII and that gCII- specific antibodies play an essential role in host defense. The presence of gCI-specific antibodies in all sera from congenitally-infected infants, and in
particular, those with persistent viruria and permanent neurological impairment, indicates that these individual antibodies may not be sufficient for recovery from persistent infection due to HCMV. EXAMPLE 5
Specific description of monoclonal antibodies comprising the monoclonal antibody cocktail
Rational for antibody selection
The gp55 (gCI)-specific mcAb MM-HCMV-9B7 was selected because it exhibits complement-dependent neutralizing activity in vitro, and can inactivate infectious virus during the extracellular phase of HCMV viremia associated with primary and reactivated HCMV infection. A second gp55 (gCI)-specific mcAb, MM-HCMV- 41C2, was included because it recognizes an epitope on gp55 in close spatial proximity on the conformational structure to the epitope recognized by mcAb 9B7 and can augment the binding and neutralizing activity of the 9B7
neutralizing mcAb to increase the therapeutic
effectiveness of that antibody. A third gCI-specific mcAb, MM-HCMV-F15-3B10, recognizes a complement- independent epitope on gp93, and can interfere with viral infectivity (i.e., block adsorption to the viral receptor expressed on target organs, prevent penetration of the virus into susceptible cells). Monoclonal antibody MM-HCMV-15F9 recognizes Group 2 gCII
glycoproteins and may prevent virion assembly and/or cell-to-cell spread which makes this mcAb useful for treating established intracellular infection.
Characterization of the HCMV-specific monoclonal antibodies in the cocktail
Immunoglobulin subtype:
MM-HCMV-41C2 and MM-HCMV-F15-3B10 are IgG1 mcAbs; MM-HCMV-9B7 is an IgG2b mcAb; MM-HCMV-15F9 is an IgG2a mcAb. Monoclonality was confirmed by isoelectric focusing.
Specificity:
All mcAbs were tested for reactivity with HCMV (glyco)proteins expressed in fibroblasts infected with several strains of HCMV, including laboratory adapted strains (Towne, AD169, Toledo), 8 wild strain isolates obtained from infants with congenital HCMV infection or adults with opportunistic HCMV infections, and several unrelated viruses including herpes simplex virus (HSV) 1 and 2, varicella zoster virus (VZV), and adenoviruses types 2 and 5. All four mcAbs were reactive with the three laboratory adapted strains and eight wild strains of HCMV, but did not show cross-reactivity with proteins expressed in cells infected with HSV, VZV, or
adenoviruses types 2 and 5, as determined by indirect immunofluorescence. In addition, all four mcAbs were tested for reactivity with a panel of cell lines of fibroblast, epithelial, and lymphoid origin, and with tissue sections from 10 different organs derived at
autopsy. No reactivity was observed which confirmed that the mcAbs were not cross-reactive with normal cellular proteins.
The gp55-specific mcAbs 97 and 41C2
immunoprecipitated unreduced gCI complexes, and also reacted with constituent glycoproteins gpl30 and gp55 in Western blot analysis. The gp93-specific mcAbs 3B10 also immunoprecipitated unreduced gCI complexes, and reacted with constituent glycoproteins gpl30 and gp93 in Western blot analysis. The gCII-specific mcAb 15F9 immunoprecipitated unreduced gCII complexes, and reacted with Group 2 gCII glycoproteins, gp38-47, gp90 and gp200 in Western blot analysis. 15F9 recognized perinuclear and cytoplasmic proteins in cells infected with Towne and AD169 strains of HCMV.
Neutralizing activity:
The neutralizing activity of the four mcAbs was examined in a quantitative plaque reduction assay using both Towne and AD169 strains of HCMV. gp55-specific mcAb 9B7 neutralized both strains in the presence of complement, whereas gp55-specific mcAb 41C2 was non- neutralizing. gp93-specific mcAb 3B10 neutralized Towne and AD169 strains of HCMV in the absence of complement. Monoclonal antibody 15F9 was non-neutralizing in the plaque reduction assay. Monoclonal antibody 9B7
exhibited greater than 50% plaque reduction at a
concentration of approximately 1 ug/ml of antibody protein, a level similar to that of three human HCMV hyperimmune globulin preparations. Neutralizing
activity was augmented 20-100 fold by the addition of 5 ug/ml of the non-neutralizing mcAb 41C2.
These mcAbs can be evaluated in
microneutralization assays to determine reduction of plaque size as a reflection of inhibition of cell-to- cell spread, quantitative plaque inhibition as a
reflection of virostatic activity, and complement- dependent lysis of chromium 51-labeled HCMV-infected
target cells alone (antibody mediated-cytolysis) or in the presence of peripheral blood mononuclear cells (antibody-dependent cellular cytotoxicity, (ADCC)) to further determine their anti-viral activity in vitro. The activities in each of these assays will indicate the appropriate functionalities mentioned above.
The specificity of these mcAbs for HCMV- infected tissues has been characterized by testing their reactivity with normal cell lines and tissues which are not infected with HCMV using an indirect
immunofluorescence assay. None of these mcAbs reacted with normal cellular proteins expressed on uninfected cell lines of fibroblast, epithelial, or lymphoid origin; nor with tissues from 10 different organs obtained at autopsy.
Mechanisms of Anti-Viral Activity:
Assays may be used to determine the potential anti-viral activity of HCMV-specific mcAbs but the extent to which this data may be extrapolated in order to define their protective activity in a human host is not yet determined. In vitro neutralization assays may be performed by pre-incubating virus with antibody in the presence or absence of complement, followed by washing and inoculation of a cell culture system in the absence of the antibody to determine if there is any residual infectious virus. Indications are that complement-dependent neutralization involves physical destruction of the virion whereas complement-independent neutralization involves selective blocking of a protein essential to the infectivity of the virus. Complement- independent neutralization may include such activity as an antibody which blocks access of a virion envelope glycoprotein to a cellular receptor wherein adsorption is prevented, or an antibody which blocks a fusion protein wherein an infectious virus is stopped from penetrating host cells. Molecular analysis of the gene encoding the gCI glycoproteins indicates that the
glycoproteins performing those functions may be the analogue of a glycoprotein in herpes simplex virus which is involved in viral fusion.
Additional assays can be utilized to determine whether non-neutralizing mcAbs exhibit virostatic antiviral activity; that is, whether a virus is non- infectious in the presence of the antibody but
infectious once the antibody is removed. In maintaining a therapeutic level of anti-viral activity throughout a period of prophylaxis or treatment, such inhibitory antibodies may be as effective as those which are virocidal (i.e., lethal to the virus). Plaque size reduction assays indicate that gcll glycoproteins and complexes may play a critical role in virion assembly and/or cell-to-cell spread. Viral inhibition assays are thereby conducted to determine the capacity of the gcll- specific mcAbs (i.e., 15F9) to prevent cytopathogenicity in cell culture when continually present. In addition, all monoclonal antibodies are examined according to two cytotoxicity assays, one of which evaluates direct lysis of HCMV-infected cells in the presence or absence of complement, and the other which determines the capacity of the antibody to mediate lymphocyte killing of virus- infected cells. Such activities not only destroy the repository for replicating intracellular virus but also protect adjacent, uninfected cells.
EXAMPLE 6
Formulation of Pharmaceutical Cocktail The formulation of the pharmaceutical cocktail is determined on the basis of in vitro reactivity of the mcAbs with multiple strains of HCMV. Various
formulations of the cocktail can be made by combining the four mcAbs in different proportions. Different dilutions of these combinations can be evaluated in a quantitative plaque reduction assay using Towne strain HCMV and in microneutralization, viral inhibition, and
cytolytic assays to confirm anti-viral activity against multiple strains of HCMV.
Cells/tissues obtained from patients or from prospective transplant material or blood products can be examined in vitro for evidence of HCMV glycoproteins. Seropositive tissues and/or sera can then be examined for sensitivity to different concentrations of various mcAbs mixtures according to in vitro anti-viral assays.
The appropriate mixture of mcAbs, as determined by the in vitro neutralization assays, can then be combined with a sterile aqueous solution containing a concentration of salt to achieve the physiological concentration found in human plasma, or with a
physiologically balanced salt solution containing protein (i.e., albumin) wherein the total concentration of protein including mcAb protein does not exceed the normal protein concentration in human plasma (i.e., 5 gm/100 ml.).
Production characteristics:
All hybridomas were subcloned at least two times by limiting dilution to ensure clonality, and were shown to stably produce HCMV-specific antibody at a level of greater than 5 mg/ml in mouse ascites. All biological and immunological characterization of these mcAbs were performed on purified IgG obtained from HPLC hydroxyl apatite chromatography.
EXAMPLE 7
"Humanized" HCMV-Specific Monoclonal Antibodies
The unique specificities and synergistic antiviral activities of component murine HCMV-specific mcAbs in the cocktail can be engineered into "humanized" mcAbs according to established methods including human-mouse B cell heterohybridomas, human-human B cell hybridomas, B lymphoblastoid cell lines by EBV transformation, and transfeetomas producing chimeric human-mouse
immunoglobulin by genetic engineering.
The unique binding specificity and functional activity of the component mcAbs are dependent on the variable regions of the heavy and light chains of the immunoglobulin molecules. Consequently, comparable humanized mcAbs must either be generated by co- transfecting variable region genes derived from murine hybridomas producing mcAbs of identical specificity with human constant region immunoglobulin genes or by
hybridization of human B cells producing antibodies of identical specificities by selective immunization and screening with the unique peptide. Since immunoglobulin molecules are bivalent, a chimeric immunoglobulin molecule can be generated exhibiting dual specificity (two sites each of which bind a different epitope). In addition, the anti-viral activity of certain mcAbs may reside in the variable region so that Fab or F(ab')2 fragments may be used rather than whole immunoglobulin. Other mcAbs, however, may require functional
determinants (i.e., complement fixation) on the constant region of the heavy chain (Fc fragment) in order to exhibit anti-viral activity. These properties should be retained in any humanized mcAb which is generated.
The invention has been described with reference to various specific and preferred embodiments and techniques. However, it should be understood that many variations and modifications may be made while remaining within the spirit and scope of the invention.
Claims
1. A cocktail composition comprising: a mixture of at least two human cytomegalovirus-specific
immunoglobulins each of which is capable of binding with a different segment of human cytomegalovirus envelope glycoproteins or complexes.
2. A cocktail composition according to claim 1 wherein the immunoglobulins are capable of reacting with different, non-competing epitopes on the same or different human cytomegalovirus envelope
glycoproteins.
3. A cocktail composition according to claim 1 wherein one of the immunoglobulins is capable of causing enhancement of the binding capacity and anti-viral activity of at least one other member of the mixture.
4. A cocktail composition according to claim 1 wherein the immunoglobulins display activity against an early and late stage of human cytomegalovirus infection.
5. A cocktail composition according to claim 1 wherein the immunoglobulins are capable of exhibiting complement-dependent and complement-independent neutralizing reactivity.
6. A composition according to claim 1 wherein at least one immunoglobulin is reactive with gp55 of the gCI glycoprotein complex of human cytomegalovirus.
7. A composition according to claim 1 wherein two of the immunoglobulins react with gp55 of the gCI glycoprotein complex of human cytomegalovirus so that the first immunoglobulin reaction augments the binding capacity and anti-viral activity of the second immunoglobulin.
8. A composition according to claim 1 wherein one
immunoglobulin reacts with a non-neutralizing epitope on gp55 of the gCI glycoprotein complex of human cytomegalovirus located in close spatial proximity to a complement-dependent neutralizing epitope on gp55 of the gCI complex so that said reaction augments a reaction of the second
immunoglobulin with the neutralizing epitope.
9. A composition according to claim 1 wherein at least one immunoglobulin is reactive with gp93 of the gCI glycoprotein complex of human cytomegalovirus.
10. A composition according to claim 1 wherein at least one immunoglobulin is reactive with a complement- independent neutralizing epitope on gp93 of the gCI glycoprotein complex of human cytomegalovirus.
11. A composition according to claim 1 wherein at least one immunoglobulin is reactive with Group 2 glycoproteins of the gCII glycoprotein complexes of human cytomegalovirus.
12. A composition according to claim 11 wherein the
immunoglobulin is reactive with gp38-47, gp90, gp200, or a combination thereof.
13. A composition according to claim 1 wherein at least one immunoglobulin is reactive with gp55 of the gCI complex of human cytomegalovirus, at least one immunoglobulin is reactive with gp93 of the gCI complex of human cytomegalovirus, and at least one immunoglobulin is reactive with Group 2 glycoproteins of the gCII glycoprotein complexes of human cytomegalovirus.
14. A composition according to claim 1 wherein the
immunoglobulins are selected from the group
consisting of monoclonal antibodies, chimeric monoclonal antibodies, bi-specific rearranged antibodies, F(ab) or F(ab')2 fragments alone or in combination with Fc fragments, human monoclonal antibodies having hypervariable segments equivalent to the hypervariable segments of a murine monoclonal antibody that is specifically immunoreactive with human cytomegalovirus, murine monoclonal antibodies, and any combination thereof.
15. A composition according to claim 1 wherein the
mixture comprises at least one IgG1 monoclonal antibody, at least one IgG2b) monoclonal antibody, and at least one IgG2a monoclonal antibody.
16. A composition according to claim 15 wherein the
monoclonal antibodies are MM-HCMV-9B7, MM-HCMV-41C2, MM-HCMV-F15-3B10, and MM-HCMV-15F9.
17. A composition according to claim 1 wherein the
mixture is capable of neutralizing or inhibiting extracellular and intracellular human
cytomegalovirus.
18. A composition according to claim 1 wherein the
mixture is capable of neutralizing or inhibiting extracellular human cytomegalovirus in the early stage of human cytomegalovirus infection and of neutralizing or inhibiting intracellular human cytomegalovirus in the late stage of human
cytomegalovirus infection.
19. A cocktail composition according to claim 1 for use as a pharmaceutical composition for treatment of human cytomegalovirus infections in humans
comprising an effective amount of the mixture and a pharmaceutically-acceptable carrier.
20. A pharmaceutical composition according to claim 19 wherein the carrier is a liquid.
21. A method of therapeutic or prophylactic treatment of a patient having or subject to a human
cytomegalovirus infection, comprising: administering to the patient a pharmaceutical composition of an effective amount of a mixture of at least two human cytomegalovirus-specific immunoglobulins in
combination with a suitable carrier wherein each of the immunoglobulins is capable of binding with a different segment of human cytomegalovirus envelope glycoproteins or complexes.
22. A method according to claim 21 wherein the
immunoglobulins are capable of reacting with
different, non-competing epitopes on the same or different human cytomegalovirus envelope
glycoproteins.
23. A method of medical treatment according to claim 21 wherein one of the immunoglobulins is capable of causing enhancement of the binding and anti-viral capacity of at least one other member of the
mixture.
24. A method according to claim 21 wherein the
immunoglobulins display activity against an early and late stage of human cytomegalovirus infection.
25. A method according to claim 21 wherein the
immunoglobulins are capable of exhibiting
complement-dependent and complement-independent neutralizing reactivity.
26. A method of medical treatment according to claim 21 wherein at least one immunoglobulin is reactive with gp55 of the gCI complex of human cytomegalovirus, at least one immunoglobulin is reactive with gp93 of the gCI complex of human cytomegalovirus , and at least one immunoglobulin is reactive with Group 2 glycoproteins of the gCII glycoprotein complexes of human cytomegalovirus.
27. A method of medical treatment according to claim 21 wherein the immunoglobulins are selected from the group consisting of monoclonal antibodies, chimeric monoclonal antibodies, bi-specific rearranged antibodies, F(ab) or F(ab')2 fragments alone or in combination with Fc fragments, human monoclonal antibodies having hypervariable segments equivalent to the hypervariable segments of a murine monoclonal antibody that is specifically immunoreactive with human cytomegalovirus, murine monoclonal antibodies, and any combination thereof.
28. A method of medical treatment according to claim 21 wherein the immunoglobulins are MM-HCMV-9B7, MM- HCMV-41C2, MM-HCMV-F15-3B10, and MM-HCMV-15F9.
29. A method of medical treatment according to claim 1 wherein the composition is administered to a patient selected from the group consisting of HIV- seropositive patients, human cytomegalovirus- seronegative pregnant women exposed to or actively infected with human cytomegalovirus, patients at risk of opportunistic human cytomegalovirus infections, organ or bone marrow transplant
patients, and any combination thereof.
30. A method of assaying for the presence of human
cytomegalovirus in a fluid or a tissue specimen obtained from a patient, comprising: combining the specimen with a composition of at least two HCMV- specific immunoglobulins in combination with a detection marker to form a bound complex carrying the marker wherein each of the immunoglobulins is capable of binding with a different segment of HCMV envelope glycoproteins or complexes, and detecting a signal from the detection marker carried by the bound complex, said signal indicating the reaction between the cytomegalovirus and at least one
immunoglobulin.
31. A method according to claim 30 wherein the
immunoglobulins are capable of reacting with
different, non-competing epitopes on the same or different human cytomegalovirus envelope
glycoproteins.
32. A method of detecting the presence of human
cytomegalovirus according to claim 30 wherein one of the immunoglobulins is capable of causing
enhancement of the binding capacity and antiviral activity of at least one other member of the
mixture.
33. A method according to claim 30 wherein the
immunoglobulins display activity against an early and late stage of human cytomegalovirus infection.
34. A method according to claim 30 wherein the
immunoglobulins are capable of exhibiting complement-dependent and complement-independent neutralizing reactivity.
35. A method of detecting the presence of human
cytomegalovirus according to claim 30 wherein at least one immunoglobulin is reactive with gp55 of the gCI complex of human cytomegalovirus, at least one immunoglobulin is reactive with gp93 of the gCI complex of human cytomegalovirus, and at least one immunoglobulin is reactive with Group 2
glycoproteins of the gCII glycoprotein complexes of human cytomegalovirus.
36. A method of detecting the presence of human
cytomegalovirus according to claim 30 wherein the immunoglobulins are selected from the group
consisting of monoclonal antibodies, chimeric monoclonal antibodies, bi-specific rearranged antibodies, F(ab) or F(ab')2 fragments alone or in combination with Fc fragments, human monoclonal antibodies having hypervariable segments equivalent to the hypervariable segments of a murine monoclonal antibody that is specifically immunoreactive with human cytomegalovirus, murine monoclonal antibodies, and any combination thereof.
37. A method of detecting the presence of human
cytomegalovirus according to claim 30 wherein the immunoglobulins are MM-HCMV-9B7, MM-HCMV-41C2, MM- HCMV-F15-3B10, and MM-HCMV-15F9.
38. A method of detecting the presence of human
cytomegalovirus according to claim 30 wherein at least one immunoglobulin is capable of causing enhancement of the binding and anti-viral capacity of at least one immunoglobulin labeled with a detection molecule.
39. A method of detecting the presence of human
cytomegalovirus according to claim 30 wherein more than one strain of human cytomegalovirus is
detected.
40. A method of detecting the presence of human
cytomegalovirus according to claim 30 wherein extracellular human cytomegalovirus, human
cytomegalovirus glycoproteins expressed on the surface of tissue, or a combination of the two are detected.
41. A method according to claim 30 wherein the combining and detecting steps incorporate an immunoassay format selected from the group consisting of radio- immunoassay, enzyme-linked immunosorbant assay, or immunofluorescence assay.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US42468589A | 1989-10-20 | 1989-10-20 | |
US424,685 | 1989-10-20 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO1991005876A1 true WO1991005876A1 (en) | 1991-05-02 |
Family
ID=23683509
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US1990/006017 WO1991005876A1 (en) | 1989-10-20 | 1990-10-19 | Human cytomegalovirus-specific monoclonal antibody cocktail |
Country Status (1)
Country | Link |
---|---|
WO (1) | WO1991005876A1 (en) |
Cited By (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7419789B2 (en) | 2002-11-05 | 2008-09-02 | Institut Pasteur | Method of inhibiting binding of Dengue virus to a human cell with DC-SIGN blockers |
US7427469B2 (en) * | 2002-11-05 | 2008-09-23 | Institut Pasteur | Method of treating cytomegalovirus with DC-SIGN blockers |
US7947274B2 (en) | 2007-01-04 | 2011-05-24 | Humabs, LLC. | Human cytomegalovirus neutralising antibodies and use thereof |
US7955599B2 (en) | 2007-01-04 | 2011-06-07 | Humabs, LLC | Human cytomegalovirus neutralizing antibodies and use thereof |
US8124093B2 (en) | 2008-07-16 | 2012-02-28 | Institute For Research In Biomedicine | Human cytomegalovirus neutralizing antibodies and use thereof |
US9346874B2 (en) | 2009-12-23 | 2016-05-24 | 4-Antibody Ag | Binding members for human cytomegalovirus |
WO2022162370A1 (en) * | 2021-01-27 | 2022-08-04 | University College Cardiff Consultants Limited | Anti-viral therapeutic |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4514505A (en) * | 1982-05-21 | 1985-04-30 | The Trustees Of Columbia University In The City Of New York | Monoclonal antibody mixtures and use thereof for enhanced sensitivity immunoassays |
US4783399A (en) * | 1984-05-04 | 1988-11-08 | Scripps Clinic And Research Foundation | Diagnostic system for the detection of cytomegalovirus |
-
1990
- 1990-10-19 WO PCT/US1990/006017 patent/WO1991005876A1/en unknown
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4514505A (en) * | 1982-05-21 | 1985-04-30 | The Trustees Of Columbia University In The City Of New York | Monoclonal antibody mixtures and use thereof for enhanced sensitivity immunoassays |
US4783399A (en) * | 1984-05-04 | 1988-11-08 | Scripps Clinic And Research Foundation | Diagnostic system for the detection of cytomegalovirus |
Non-Patent Citations (10)
Cited By (32)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7427469B2 (en) * | 2002-11-05 | 2008-09-23 | Institut Pasteur | Method of treating cytomegalovirus with DC-SIGN blockers |
US7419789B2 (en) | 2002-11-05 | 2008-09-02 | Institut Pasteur | Method of inhibiting binding of Dengue virus to a human cell with DC-SIGN blockers |
US8545848B2 (en) | 2007-01-04 | 2013-10-01 | Institute For Research In Biomedicine | Human cytomegalovirus neutralising antibodies and use thereof |
US7947274B2 (en) | 2007-01-04 | 2011-05-24 | Humabs, LLC. | Human cytomegalovirus neutralising antibodies and use thereof |
US7955599B2 (en) | 2007-01-04 | 2011-06-07 | Humabs, LLC | Human cytomegalovirus neutralizing antibodies and use thereof |
US9611316B2 (en) | 2007-01-04 | 2017-04-04 | Institute For Research In Biomedicine | Human cytomegalovirus neutralising antibodies and use thereof |
US8298538B2 (en) | 2007-01-04 | 2012-10-30 | Institute For Research In Biomedicine | Human cytomegalovirus neutralising antibodies and use thereof |
US9217028B2 (en) | 2007-01-04 | 2015-12-22 | Institute For Research In Biomedicine | Human cytomegalovirus neutralising antibodies and use thereof |
US8309089B2 (en) | 2007-01-04 | 2012-11-13 | Institute For Research In Biomedicine | Human cytomegalovirus neutralising antibodies and use thereof |
US9149524B2 (en) | 2007-01-04 | 2015-10-06 | Institute For Research In Biomedicine | Human cytomegalovirus neutralising antibodies and use thereof |
US9221897B2 (en) | 2008-07-16 | 2015-12-29 | Institute For Research In Biomedicine | Human cytomegalovirus neutralizing antibodies and use thereof |
US9491906B2 (en) | 2008-07-16 | 2016-11-15 | Institute For Research In Biomedicine | Human cytomegalovirus neutralizing antibodies and use thereof |
US8765132B2 (en) | 2008-07-16 | 2014-07-01 | Institute For Research In Biomedicine | Human cytomegalovirus neutralizing antibodies and use thereof |
US9127049B2 (en) | 2008-07-16 | 2015-09-08 | Institute For Research In Biomedicine | Human cytomegalovirus neutralizing antibodies and use thereof |
US8435524B2 (en) | 2008-07-16 | 2013-05-07 | Institute For Research In Biomedicine | Human cytomegalovirus neutralizing antibodies and use thereof |
US8298539B2 (en) | 2008-07-16 | 2012-10-30 | Institute For Research In Biomedicine | Human cytomegalovirus neutralizing antibodies and use thereof |
US8287870B2 (en) | 2008-07-16 | 2012-10-16 | Institute For Research In Biomedicine | Human cytomegalovirus neutralizing antibodies and use thereof |
US9249213B2 (en) | 2008-07-16 | 2016-02-02 | Institute For Research In Biomedicine | Human cytomegalovirus neutralizing antibodies and use thereof |
US10889632B2 (en) | 2008-07-16 | 2021-01-12 | Institute For Research In Biomedicine | Human cytomegalovirus neutralizing antibodies and use thereof |
US9365636B1 (en) | 2008-07-16 | 2016-06-14 | Institute For Research In Biomedicine | Human cytomegalovirus neutralizing antibodies and use thereof |
US9371372B2 (en) | 2008-07-16 | 2016-06-21 | Institute For Research In Biomedicine | Human cytomegalovirus neutralizing antibodies and use thereof |
US8603480B2 (en) | 2008-07-16 | 2013-12-10 | Institute For Research In Biomedicine | Human cytomegalovirus neutralizing antibodies and use thereof |
US9527902B2 (en) | 2008-07-16 | 2016-12-27 | Institute For Research In Biomedicine | Human cytomegalovirus neutralizing antibodies and use thereof |
US8124093B2 (en) | 2008-07-16 | 2012-02-28 | Institute For Research In Biomedicine | Human cytomegalovirus neutralizing antibodies and use thereof |
US9725502B2 (en) | 2008-07-16 | 2017-08-08 | Institute For Research In Biomedicine | Human cytomegalovirus neutralizing antibodies and use thereof |
US9796772B2 (en) | 2008-07-16 | 2017-10-24 | Institute For Research In Biomedicine | Human cytomegalovirus neutralizing antibodies and use thereof |
US9796771B2 (en) | 2008-07-16 | 2017-10-24 | Institute For Research In Biomedicine | Human cytomegalovirus neutralizing antibodies and use thereof |
US9803000B1 (en) | 2008-07-16 | 2017-10-31 | Institute of Research in Biomedicine | Human cytomegalovirus neutralizing antibodies and use thereof |
US10040845B2 (en) | 2008-07-16 | 2018-08-07 | Institute For Research In Biomedicine | Human cytomegalovirus neutralizing antibodies and use thereof |
US10414817B2 (en) | 2008-07-16 | 2019-09-17 | Institute For Research In Biomedicine | Human cytomegalovirus neutralizing antibodies and use thereof |
US9346874B2 (en) | 2009-12-23 | 2016-05-24 | 4-Antibody Ag | Binding members for human cytomegalovirus |
WO2022162370A1 (en) * | 2021-01-27 | 2022-08-04 | University College Cardiff Consultants Limited | Anti-viral therapeutic |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP6062477B2 (en) | Human cytomegalovirus neutralizing antibody and use thereof | |
RU2542472C2 (en) | Monoclonal antibody able to bind to specific discontinuous epitope placed in ad1 region of human cytomegalovirus gb glycoprotein, and its antigen-binding fragment | |
US20210388065A1 (en) | Antibodies to sars-coronavirus (covid-19) s1 spike protein | |
EP0690132A1 (en) | Anti-hiv monoclonal antibody | |
KR920008744B1 (en) | Monoclonal antibodies to hiv and related peptides | |
US5126130A (en) | Monoclonal antibodies reactive with specific antigenic sites on human cytomegalovirus glycoprotein a | |
KR20140041951A (en) | Human cytomegalovirus neutralising antibodies and use thereof | |
US5607847A (en) | Recombinant human anti-human immunodeficiency virus antibody | |
JP2626680B2 (en) | Human monoclonal antibody against lymph node damage related virus | |
RU2128222C1 (en) | Murine monoclonal antibody nmo1, hybridoma cellular line, fragment of murine monoclonal antibody (variants) | |
AU695584B2 (en) | Human monoclonal antibodies to cytomegalovirus | |
WO1991005876A1 (en) | Human cytomegalovirus-specific monoclonal antibody cocktail | |
WO2021248279A1 (en) | Antibodies against sars-cov-2 s1 spike protein | |
CA2168230A1 (en) | Human antibodies against varicella-zoster virus | |
Azuma et al. | Phase I study on human monoclonal antibody against cytomegalovirus: pharmacokinetics and immunogenicity | |
JPH05506561A (en) | HIV-1 MN gp120 human monoclonal antibody | |
Neurath et al. | 3-Hydroxyphthaloyl β-lactoglobulin. III. Antiviral activity against herpesviruses | |
US5248768A (en) | Immunogenic glycoproteins of human cytomegalovirus | |
WO1991002004A1 (en) | IMMUNOGENIC GLYCOPROTEINS OF HUMAN CYTOMEGALOVIRUS gCII | |
CN117209608A (en) | CD 47-targeting antibody and application thereof | |
WO1991004277A1 (en) | Monoclonal antibodies specific to cytomegalovirus glycoprotein | |
WO1994010294A1 (en) | Human monoclonal antibodies to human parvovirus and methods of making and using thereof | |
WO1989001628A1 (en) | Monoclonal antibodies reactive with cytomegalovirus glycoprotein a | |
Masuho et al. | Development of a human monoclonal antibody against cytomegalovirus with the aim of a passive immunotherapy | |
Tomiyama et al. | Antiviral activities of a human monoclonal antibody against human cytomegalovirus |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): CA JP |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): AT BE CH DE DK ES FR GB GR IT LU NL SE |
|
NENP | Non-entry into the national phase |
Ref country code: CA |